[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 91 of about 91
1. Mirza SB, Puttasidiah P, Panesar SS, French JA, Jones DR, Stock D: Sarcoma of the bladder with metastasis to the left ventricle. Can Urol Assoc J; 2008 Apr;2(2):143-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcoma of the bladder with metastasis to the left ventricle.
  • Cardiac metastasis from genitourinary tumours in general is an exceedingly rare phenomenon and has previously been reported only in relation to carcinomas.
  • We report the first case of sarcoma of the bladder with metastasis to the heart causing sudden death.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Oncol. 2000 May;17(2):147-50 [10871822.001]
  • [Cites] Urology. 2003 Jun;61(6):1151-5 [12809885.001]
  • [Cites] J Urol. 1992 Apr;147(4):1032-6; discussion 1036-7 [1552580.001]
  • [Cites] J Urol. 1988 Dec;140(6):1397-9 [3143017.001]
  • [Cites] J Urol. 1985 Jan;133(1):29-30 [3964876.001]
  • [Cites] Br J Urol. 1997 Nov;80(5):831-2 [9393319.001]
  • [Cites] Int J Cardiol. 1985 Jun;8(2):205-8 [4008108.001]
  • [Cites] J Urol. 1978 Jan;119(1):72-6 [621819.001]
  • [Cites] J Clin Ultrasound. 1980 Feb;8(1):49-51 [6766477.001]
  • [Cites] Urology. 1995 Feb;45(2):320-2 [7855982.001]
  • [Cites] J Urol. 1985 Feb;133(2):200-2 [3968731.001]
  • (PMID = 18542751.001).
  • [ISSN] 1911-6470
  • [Journal-full-title] Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • [ISO-abbreviation] Can Urol Assoc J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2422910
  •  go-up   go-down


2. Masue T, Taniguchi M, Takeuchi T, Sakai S: [A case report of sarcomatoid carcinoma of the bladder with metastasis to small intestine]. Nihon Hinyokika Gakkai Zasshi; 2005 Sep;96(6):640-3
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of sarcomatoid carcinoma of the bladder with metastasis to small intestine].
  • Cystoscopic examination revealed a broad-based tumor of 2.5 cm in diameter on the lateral side of the right ureteral orifice.
  • Under the clinical diagnosis of TCC G2 > G3, T3bNOM0, radical cystectomy with orthotopic bladder substitution was performed.
  • Pathological diagnosis was TCC G3 with sarcomatoid carcinoma, pT2pR0pL1 pVlpN0.
  • Lung metastasis was observed 6 months postoperatively.
  • Despite of M-VAC therapy and radiation therapy, additional metastases to brain and liver were observed.
  • To our knowledge, this is the first case of sarcomatoid carcinoma of the bladder with metastasis to small intestine, although 6 cases of transitional cell carcinoma of the bladder with metastasis to small intestine has been reported in Japan.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Carcinosarcoma / secondary. Ileal Neoplasms / secondary. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16218407.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 11
  •  go-up   go-down


3. Taverna G, Corinti M, Colombo P, Grizzi F, Severo M, Piccinelli A, Giusti G, Benetti A, Zucali PA, Graziotti P: Bladder metastases of appendiceal mucinous adenocarcinoma: a case presentation. BMC Cancer; 2010;10:62
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder metastases of appendiceal mucinous adenocarcinoma: a case presentation.
  • Few cases of appendiceal carcinoma infiltrating the bladder wall for spatial contiguity have been documented.
  • CASE PRESENTATION: A case is reported of a 45-years old woman with mucinous cystadenocarcinoma of the appendix with bladder metastasis.
  • Although ultrasonography and voided urinary cytology were negative, abdomen computed tomography (CT) scan and cystoscopy and subsequent pathological examination revealed a mass exclusively located in the anterior wall of the bladder.
  • Histopathology of the transurethral bladder resection revealed a bladder adenocarcinoma [6 cm (at the maximum diameter) x 2,5 cm; approximate weight: 10 gr] with focal mucinous aspects penetrating the muscle and perivisceral fat.
  • The subsequent pathological examination revealed a mucinous cystadenocarcinoma of the appendix with metastatic cells colonising the anterior bladder wall and several colic lymph nodes.
  • CONCLUSIONS: The rarity of the appendiceal carcinoma invading the urinary bladder and its usual involvement of nearest organs and the posterior bladder wall, led us to describe this case which demonstrates the ability of the appendiceal cancer to metastasize different regions of urinary bladder.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Cystadenocarcinoma, Mucinous / secondary. Urinary Bladder Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Urol. 2001 Apr;8(4):196-8 [11260355.001]
  • [Cites] Hinyokika Kiyo. 2002 Jun;48(6):351-4 [12166235.001]
  • [Cites] J Urol. 1980 Apr;123(4):590-1 [6245280.001]
  • [Cites] Can J Surg. 1982 Sep;25(5):553-5 [7116255.001]
  • [Cites] J Urol. 1987 Sep;138(3):617-8 [3041057.001]
  • [Cites] J Dig Dis. 2008 Aug;9(3):175-7 [18956597.001]
  • [Cites] Br J Urol. 1996 Aug;78(2):305-6 [8813936.001]
  • [Cites] Urol Int. 1997;58(2):124-7 [9096277.001]
  • [Cites] World J Gastroenterol. 2005 Aug 14;11(30):4761-3 [16094726.001]
  • [Cites] Int Urol Nephrol. 2006;38(3-4):481-2 [17160444.001]
  • [Cites] J Urol. 1995 Apr;153(4):1220-1 [7869505.001]
  • (PMID = 20178637.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2836301
  •  go-up   go-down


Advertisement
4. Melegari S, Albo G, Rocco B, Verweij F, Abbinante M, de Cobelli O: Metachronous bladder metastases from renal cell carcinoma: a case report and review of the literature. Ecancermedicalscience; 2010;4:175

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous bladder metastases from renal cell carcinoma: a case report and review of the literature.
  • INTRODUCTION: adrenal gland, parotid gland, pharynx, eye and bladder are rare localizations of metastases of renal cell carcinoma (RCC).
  • We report a case of metachronous RCC metastases to the bladder in a patient with a medical history of transitional cell carcinoma (TCC) of the bladder.
  • The histology of the resected sample was confirmed to be RCC, comparable to a primary kidney cancer and not recurrent TCC.
  • CONCLUSION: the patient had a probability of metastases three years after nephrectomy of 62.9%.
  • Survival rates following single metastasectomy are 60% and 38% at three and five years, respectively; metachronous diagnosis has a better prognosis than synchronous.
  • During RCC follow-up, each lesion should be considered as a possible metastasis of RCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22276029.001).
  • [ISSN] 1754-6605
  • [Journal-full-title] Ecancermedicalscience
  • [ISO-abbreviation] Ecancermedicalscience
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3234030
  •  go-up   go-down


5. Gatti G, Zurrida S, Gilardi D, Bassani G, dos Santos GR, Luini A: Urinary bladder metastases from breast carcinoma: review of the literature starting from a clinical case. Tumori; 2005 May-Jun;91(3):283-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary bladder metastases from breast carcinoma: review of the literature starting from a clinical case.
  • Bladder metastases from solid tumors are rare.
  • Breast carcinoma cells seldom spread to the urinary bladder.
  • We report the case of a patient with invasive breast carcinoma who developed a breast recurrence followed by bone and urinary bladder metastases.
  • Only few cases of urinary bladder metastases from primary breast cancer have been reported, although the case reports have increased in recent years.
  • Patients with breast cancer presenting with urinary symptoms should be examined for possible bladder metastases.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / secondary. Urinary Bladder Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206659.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 27
  •  go-up   go-down


6. Kato S, Ito Y, Nishino Y, Ban Y, Deguchi T: [Urethral recurrence and distant metastases of bladder cancer 9 years after cystectomy and neobladder]. Hinyokika Kiyo; 2005 Mar;51(3):195-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urethral recurrence and distant metastases of bladder cancer 9 years after cystectomy and neobladder].
  • We report a 79-year-old female with urethral recurrence and distant metastases of urothelial bladder cancer.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy. Lymph Nodes / pathology. Urethral Neoplasms / secondary. Urinary Bladder Neoplasms / surgery. Urinary Diversion
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis

  • Genetic Alliance. consumer health - Urethral cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852676.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Onuigbo MA: Symptomatic uraemia from bilateral obstructive uropathy secondary to metastatic urinary bladder cancer showing only unilateral hydronephrosis: a case report. NDT Plus; 2009 Oct;2(5):387-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptomatic uraemia from bilateral obstructive uropathy secondary to metastatic urinary bladder cancer showing only unilateral hydronephrosis: a case report.
  • Recently, a patient presented with uraemia and metastatic urinary bladder carcinoma but only unilateral right-sided hydronephrosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25949352.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC4421382
  • [Keywords] NOTNLM ; metastatic urinary bladder cancer / nondilated obstructive uropathy / unilateral hydronephrosis / uraemia
  •  go-up   go-down


8. Jones TD, Carr MD, Eble JN, Wang M, Lopez-Beltran A, Cheng L: Clonal origin of lymph node metastases in bladder carcinoma. Cancer; 2005 Nov 1;104(9):1901-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal origin of lymph node metastases in bladder carcinoma.
  • BACKGROUND: Evidence of genetic heterogeneity within urothelial carcinomas of the bladder has raised questions about the clonal origin of urothelial carcinoma and its metastases.
  • High-grade urothelial carcinoma of the bladder frequently metastasizes to multiple regional lymph nodes in the pelvis.
  • Whether or not these multiple lymph node metastases originate from the same tumor clone is uncertain.
  • Molecular analysis of microsatellite alterations and X-chromosome inactivation status of distinct tumor cell populations from the same patient may further our understanding of the genetic basis of carcinoma progression and metastasis.
  • All patients had multiple (from two to four) lymph node metastases.
  • Loss of heterozygosity (LOH) assays for 3 microsatellite polymorphic markers on chromosome 9p21 (D9S171, region of putative tumor suppressor gene p16), 9q32 (D9S177, putative tumor suppressor gene involved in urothelial carcinoma tumorigenesis), and 17p13 (TP53, the p53 locus) were performed.
  • In addition, X-chromosome inactivation analysis was performed in primary tumors and metastases from 10 female patients.
  • The overall frequency of allelic loss was 67% (16 of 24 tumors) in the primary urothelial carcinomas and 79% (19 of 24 tumors) in the metastatic carcinomas.
  • LOH in > or = 1 lymph node metastases was seen at the D9S171, D9S177, and TP53 loci in 35% (8 of 23 tumors), 45% (9 of 20 tumors), and 48% (11 of 23 tumors) of informative samples, respectively.
  • Eleven tumors demonstrated identical allelic loss patterns at all DNA loci both in the primary carcinoma and in all corresponding lymph node metastases.
  • Three tumors showed allelic loss in the metastatic carcinoma but not in its matched primary carcinoma.
  • Six tumors demonstrated a different LOH pattern in each of its lymph node metastases.
  • Clonality analysis showed the same pattern of nonrandom X-chromosome inactivation both in the primary urothelial carcinoma and in all of the lymph node metastases in five of nine informative tumors studied.
  • Four tumors showed a random pattern of X-chromosome inactivation in both the primary carcinoma and in the metastases.
  • CONCLUSIONS: LOH and X-chromosome inactivation assays showed that multiple lymph node metastases and matched primary urothelial carcinomas of the bladder had the same clonal origin, suggesting that the capability for metastasis often arises in only a single clonal population in the primary tumor.
  • [MeSH-major] Clone Cells. Lymphatic Metastasis / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16196038.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Zagha RM, Hamawy KJ: Solitary breast cancer metastasis to the bladder: an unusual occurrence. Urol Oncol; 2007 May-Jun;25(3):236-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary breast cancer metastasis to the bladder: an unusual occurrence.
  • Breast carcinoma is the most common nondermatologic cancer diagnosis in women.
  • Common metastatic sites include lymph nodes, lung, liver, and bone.
  • Metastases to the bladder are exceedingly rare.
  • To date, there are a total of 31 reports of patients diagnosed with metastatic breast cancer to the bladder while living.
  • Only 5 of these patients were reported to have no other site of metastasis, other than axillary nodes at breast surgery.
  • We present the sixth reported case of metastatic breast carcinoma solely to the bladder in a living patient.
  • [MeSH-major] Breast Neoplasms / pathology. Urinary Bladder Neoplasms / secondary


10. Sekiya M, Ichikawa M, Tsutsui A, Yoshimi K, Suzuki T, Seyama K, Uekusa T, Takahashi K: [A case of pulmonary metastases from bladder cancer, suspected of recurrent Wegener's granulomatosis]. Nihon Kokyuki Gakkai Zasshi; 2009 Oct;47(10):943-6
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pulmonary metastases from bladder cancer, suspected of recurrent Wegener's granulomatosis].
  • A 26-year-old-woman was given a diagnosis of Wegener's granulomatosis and began treatment by both prednisolone and cyclophosphamide at another institution.
  • A diagnosis of pulmonary metastases from bladder cancer was established with radiological and histological examinations obtained by transbronchial lung biopsy (TBLB) and transurethral resection of the bladder tumor (TUR-Bt).
  • She had already received a total dose of 120 g of cyclophosphamide, which could be related to the development of bladder cancer.
  • On detecting multiple pulmonary nodules in patients with Wegener's granulomatosis treated with cyclophosphamide, it is necessary to consider the possibility of pulmonary metastases form urinary bladder cancer.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Granulomatosis with Polyangiitis / diagnosis. Lung Neoplasms / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Cyclophosphamide / adverse effects. Diagnosis, Differential. Female. Humans. Recurrence


11. Zangrilli A, Saraceno R, Sarmati L, Orlandi A, Bianchi L, Chimenti S: Erysipeloid cutaneous metastasis from bladder carcinoma. Eur J Dermatol; 2007 Nov-Dec;17(6):534-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erysipeloid cutaneous metastasis from bladder carcinoma.
  • Cutaneous metastases from bladder cancer are uncommon, especially in the female population.
  • We describe a 56-year-old female with a history of bladder adenocarcinoma (T3N0M0) who presented erythematous plaques with an erysipelas-like appearance located on the groins and thighs.
  • Histopathology and immunohistochemistry from skin lesions were consistent with metastases from bladder carcinoma.
  • We report this case for the unusual clinical features and because an early recognition of cutaneous metastases from genitourinary malignancies is important in clinical practice.
  • [MeSH-major] Adenocarcinoma / secondary. Skin Neoplasms / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Erysipelas / diagnosis. Female. Humans. Immunohistochemistry. Middle Aged

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17951136.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


12. Pandey D, Kane SV, Shukla PJ, Shrikhande SV, Tongaonkar HB: Isolated gall bladder metastasis from renal cell carcinoma. Indian J Gastroenterol; 2006 May-Jun;25(3):161-2
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated gall bladder metastasis from renal cell carcinoma.
  • Gall bladder metastasis from renal cell carcinoma is rare.
  • We report a 46-year-old man with isolated gall bladder metastasis from renal cell carcinoma 11 months after radical nephrectomy.
  • He underwent cholecystectomy and frozen section revealed the metastatic tumor.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Gallbladder Neoplasms / secondary. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16877838.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


13. Sugawara Y, Kajihara M, Semba T, Ochi T, Fujii T, Mochizuki T: Healing focal "flare" phenomenon after radiotherapy in a bone metastasis from bladder cancer. Clin Nucl Med; 2005 Oct;30(10):672-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Healing focal "flare" phenomenon after radiotherapy in a bone metastasis from bladder cancer.
  • It has been well documented in patients with metastatic breast or prostate carcinoma, and recently reported in those with lung cancer.
  • We present a case of bone metastasis from bladder carcinoma, in which healing flare phenomenon was observed after radiotherapy.
  • [MeSH-major] Bone Neoplasms / etiology. Bone Neoplasms / secondary. Carcinoma / etiology. Carcinoma / secondary. Neoplasms, Radiation-Induced / etiology. Radiotherapy / adverse effects
  • [MeSH-minor] Aged. Humans. Male. Urinary Bladder Neoplasms / surgery


14. Dogra P, Kumar A, Singh A: An unusual case of Von Hipple Lindau (VHL) syndrome with bilateral multicentric renal cell carcinoma with synchronous solitary urinary bladder metastasis. Int Urol Nephrol; 2007;39(1):11-4
MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of Von Hipple Lindau (VHL) syndrome with bilateral multicentric renal cell carcinoma with synchronous solitary urinary bladder metastasis.
  • Synchronous solitary urinary bladder metastasis from renal cell carcinoma is extremely rare.
  • We report an unusual case of VHL with bilateral multicentric renal cell carcinoma and synchronous solitary urinary bladder metastasis.
  • [MeSH-major] Carcinoma, Renal Cell / complications. Kidney Neoplasms / complications. Neoplasms, Multiple Primary / secondary. Urinary Bladder Neoplasms / secondary. von Hippel-Lindau Disease / complications

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268895.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


15. Li Z, Qi F, Miao J, Zu X, He W, Wang L, Qi L: Vascular endothelial growth factor-C associated with computed tomography used in the diagnosis of lymph node metastasis of bladder carcinoma. Arch Med Res; 2010 Nov;41(8):606-10
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor-C associated with computed tomography used in the diagnosis of lymph node metastasis of bladder carcinoma.
  • The purpose of this study is to determine whether VEGF-C associated with computed tomography (CT) has a relationship with lymph node metastasis in bladder transitional cell carcinoma (BTCC).
  • METHODS: One hundred twenty seven cases of BTCC were studied: first, both plain and enhanced CT scans of abdomen and pelvis were performed preoperatively; second, VEGF-C protein expressions in tumor cells were tested by immunohistochemistry postoperatively; and finally, detailed pathological findings for lymph node metastasis were recorded.
  • RESULTS: VEGF-C expressions in tumor bladder cells were significantly higher than those in normal bladder epithelium.
  • In the group of BTCC-positive, VEGF-C was significantly correlated with lymph node metastasis (p <0.01).
  • Sensitivity, specificity and accuracy of VEGF-C in the diagnosis of lymph node metastasis of bladder carcinoma were 87.0, 67.9, and 74.8%, respectively.
  • When VEGF-C visually correlated with CT scan in the detection of lymph node metastasis, sensitivity was 91.3%; specificity was 84.0% and accuracy was 86.6%.
  • CONCLUSIONS: Positive VEGF-C was significantly correlated with lymph node metastasis of bladder carcinoma.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / pathology. Urinary Bladder Neoplasms / pathology. Vascular Endothelial Growth Factor C / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 IMSS. Published by Elsevier Inc. All rights reserved.
  • [CommentIn] J Urol. 2011 Dec;186(6):2212-3 [22078583.001]
  • (PMID = 21199729.001).
  • [ISSN] 1873-5487
  • [Journal-full-title] Archives of medical research
  • [ISO-abbreviation] Arch. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


16. Simms MS, Mann G, Kockelbergh RC, Mellon JK: The management of lymph node metastasis from bladder cancer. Eur J Surg Oncol; 2005 May;31(4):348-56
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of lymph node metastasis from bladder cancer.
  • AIM: The presence of pelvic lymph node metastasis from bladder cancer has traditionally been associated with a very poor prognosis.
  • The aim of this paper is to review the literature with regard to the management of patients with nodal disease, particularly gross nodal metastasis and suggest a strategy for management of these patients.
  • METHODS: We performed a literature search in the PubMed database and the reference lists of relevant papers describing the management of locally advanced bladder cancer.
  • FINDINGS: There are no randomised studies relating specifically to the management of nodal metastasis in bladder cancer.
  • The prognosis of such patients relates to the pathological stage of the primary tumour and the degree of lymph node involvement.
  • CONCLUSIONS: The prognosis for patients with gross nodal disease from bladder cancer is poor although cure may be possible in a small number of patients.
  • [MeSH-major] Lymphatic Metastasis. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Lymph Node Excision. Neoplasm Staging. Pelvis. Prognosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837038.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 60
  •  go-up   go-down


17. Kazarians B, Kausch I, Noack F, Junker K, Jocham D, Doehn C: [Atypical metastasis of renal cell carcinoma. Contribution of comparative genomic hybridisation to diagnosis]. Urologe A; 2010 Mar;49(3):407-10
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Atypical metastasis of renal cell carcinoma. Contribution of comparative genomic hybridisation to diagnosis].
  • In patients younger than 40 years, renal cell carcinoma and metastases to the bladder are rare.
  • Comparative genomic hybridisation (CGH) may be useful to differentiate between metastatic renal cell carcinoma and secondary malignancies of the genitourinary tract, which can occur in all histologic types.
  • We report the case of a 35-year-old patient with renal cell carcinoma in whom only CGH could help differentiate between a second primary malignancy in the bladder and an atypical bladder metastasis.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / diagnosis. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / secondary

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20094700.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Tsiriopoulos I, Lee G, O' Reilly A, Smith R, Pancharatnam M: Primary splenic marginal zone lymphoma with bladder metastases mimicking interstitial cystitis. Int Urol Nephrol; 2006;38(3-4):475-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary splenic marginal zone lymphoma with bladder metastases mimicking interstitial cystitis.
  • We report the case of a 76-year-old patient with a past medical history of low-grade chronic lymphocytic leukaemia who presented with severe chronic bladder symptoms attributed to interstitial cystitis.
  • Bladder histopathology revealed primary splenic marginal zone lymphoma.
  • Literature review shows the rarity of such non-hematopoietic visceral metastases.
  • This may represent the first reported splenic marginal zone lymphoma with bladder involvement and highlights the clinical and histological similarities with interstitial cystitis.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Splenic Neoplasms / pathology. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Aged. Cystitis, Interstitial. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Interstitial cystitis.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033884.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Hungary
  • [Number-of-references] 3
  •  go-up   go-down


19. Takagi M, Saito K, Yano H, Tai H, Akiba T: [Case of multiple thin-walled cavitary pulmonary metastasis from bladder cancer]. Nihon Kokyuki Gakkai Zasshi; 2006 Oct;44(10):771-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of multiple thin-walled cavitary pulmonary metastasis from bladder cancer].
  • Cystoscopy revealed a bladder tumor.
  • Transurethral resection of the bladder tumor (TUR-Bt) was performed.
  • This tumor was diagnosed pathologically as bladder cancer (transitional cell carcinoma pT2).
  • A diagnosis of pulmonary metastasis from bladder cancer was made.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17087348.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Murakami M, Nagano H, Kobayashi S, Marubashi S, Noda T, Tomimaru T, Takeda Y, Tanemura M, Kitagawa T, Dono K, Umeshita K, Wakasa K, Monden M, Doki Y, Mori M: [A case of hepatocellular carcinoma with gall bladder metastasis]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2089-91
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of hepatocellular carcinoma with gall bladder metastasis].
  • CT and MRI scan showed the tumor was located mainly in posterior segment and had portal vein tumor thrombus, and the wall of gall bladder was edematous and thick, but seemed not to be close to the main tumor.
  • We performed an extended posterior segmentectomy, tumor thrombectomy and cholecystectomy.
  • Pathological examination showed that poorly differentiated hepatocellular carcinoma cells, which were same as the main tumor, existed in lamina propria and muscle layer of gall bladder, and invaded the submucosal vessels.
  • So we diagnosed it as gall bladder metastasis from hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Gallbladder Neoplasms / secondary. Liver Neoplasms / pathology
  • [MeSH-minor] Aged. Antibodies / blood. Antibodies / immunology. Biomarkers, Tumor / blood. Hepatectomy. Hepatitis C / immunology. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed. Treatment Failure

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106533.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor
  •  go-up   go-down


21. Capdevila J, Maroto P, Algaba F, Lerma E, Villavicencio H: [Mixed transitional cell and small cell carcinoma of the bladder with metastases with neuroendocrine histology only. Case report and bibliography review]. Arch Esp Urol; 2007 Apr;60(3):306-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mixed transitional cell and small cell carcinoma of the bladder with metastases with neuroendocrine histology only. Case report and bibliography review].
  • [Transliterated title] Carcinoma mixto de uroteuo y celula pequeña de vejiga urinaria: metastasis de la histología neuroendocrina sola. Comunicación del caso y revisión de la uteratura.
  • OBJECTIVE: To report one case of transitional cell carcinoma with areas of small cell carcinoma presenting in its evolution an adrenal metastasis with the neuroendocrine component only.
  • We perform a bibliography review for the cases of small cell carcinoma of the bladder, its epidemiology, prognosis and treatment.
  • RESULTS: Small cell carcinoma of the bladder is a rare entity with a more aggressive behaviour and poorer prognosis than transitional cell carcinoma.
  • The pathologic characteristics allow differentiation of primary tumor and metastatic disease.
  • CONCLUSIONS: There is no standard treatment for small cell carcinoma of the bladder.
  • For metastatic disease the most commonly used combination is cisplatin and etoposide.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Carcinoma, Transitional Cell / pathology. Neoplasms, Multiple Primary / pathology. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601310.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 9
  •  go-up   go-down


22. Wu X, Kakehi Y, Zeng Y, Taoka R, Tsunemori H, Inui M: Uroplakin II as a promising marker for molecular diagnosis of nodal metastases from bladder cancer: comparison with cytokeratin 20. J Urol; 2005 Dec;174(6):2138-42, discussion 2142-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uroplakin II as a promising marker for molecular diagnosis of nodal metastases from bladder cancer: comparison with cytokeratin 20.
  • We performed a systemic study of uroplakin II (UP II) and cytokeratin 20 (CK 20) expression in pelvic lymph nodes on multiple sides in patients with bladder cancer.
  • MATERIALS AND METHODS: A total of 82 pelvic lymph node and 19 bladder tumor samples were obtained from 21 patients with bladder cancer by radical cystectomy with pelvic lymphadenectomy for reverse transcriptase-polymerase chain reaction assay.
  • RESULTS: Of the 19 bladder tumor tissue specimens 19 (100%) and 13 (68.4%) were positive for UP II and CK 20 mRNA expression, respectively.
  • UP II mRNA was detected in 15 of 16 pelvic lymph node samples (93.8%) with pathologically proven metastases, whereas 9 (56.6%) were positive for CK 20 mRNA.
  • The reverse transcriptase-polymerase chain reaction assay for UP II was statistically more sensitive than that for CK 20 in detecting not only primary tumors, but also metastatic pelvic lymph nodes (p = 0.0179 and 0.0373, respectively).
  • Of 66 pelvic lymph node samples without metastasis UP II was detected in 6 (10%), while CK 20 was not.
  • In addition, UP II and CK 20 mRNA could be detected in at least 50 and 500 bladder cancer HT1197 cells, respectively.
  • CONCLUSIONS: These results indicate that UP II might be a more useful marker than CK 20 for detecting micrometastases of bladder cancer in the pelvic lymph nodes, although a greater number of patients and longer followup are needed to come to a definitive conclusion.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Keratins / metabolism. Lymph Nodes / metabolism. Lymph Nodes / pathology. Membrane Proteins / metabolism. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Japan. Keratin-20. Lymphatic Metastasis / diagnosis. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Uroplakin II

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16280744.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT20 protein, human; 0 / Keratin-20; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / UPK2 protein, human; 0 / Uroplakin II; 68238-35-7 / Keratins
  •  go-up   go-down


23. Liedberg F, Månsson W: Lymph node metastasis in bladder cancer. Eur Urol; 2006 Jan;49(1):13-21
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node metastasis in bladder cancer.
  • OBJECTIVE: We reviewed the literature on nodal staging in patients with bladder cancer treated with radical cystectomy and lymphadenectomy.
  • That approach might be beneficial, especially in cases of T3/T4a tumours, which more often have lymph node metastases above the iliac bifurcation as compared to less advanced tumours.
  • [MeSH-major] Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Humans. Lymph Node Excision. Lymphatic Metastasis

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203077.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 68
  •  go-up   go-down


24. McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, Siefker-Radtke A, Dinney C: Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev; 2009 Dec;28(3-4):335-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer.
  • At the molecular level, EMT is characterized by loss of E-cadherin and increased expression of several transcriptional repressors of E-cadherin expression (Zeb-1, Zeb-2, Twist, Snail, and Slug).
  • Early work established that loss of E-cadherin and increased expression of MMP-9 was associated with a poor clinical outcome in patients with urothelial tumors, suggesting that EMT might also be associated with bladder cancer progression and metastasis.
  • More recently, we have used global gene expression profiling to characterize the molecular heterogeneity in human urothelial cancer cell lines (n = 20) and primary patient tumors, and unsupervised clustering analyses revealed that the cells naturally segregate into two discrete "epithelial" and "mesenchymal" subsets, the latter consisting entirely of muscle-invasive tumors.
  • The results suggest that EMT coordinately regulates drug resistance and muscle invasion/metastasis in urothelial cancer and is a dominant feature of overall cancer biology.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Cell Transdifferentiation / physiology. Drug Resistance, Neoplasm. Epithelium / pathology. Mesoderm / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Cadherins / physiology. Cell Line, Tumor / pathology. Disease Progression. Fibroblast Growth Factor 3 / physiology. Gene Expression Profiling. Gene Expression Regulation, Developmental. Gene Expression Regulation, Neoplastic. Humans. MicroRNAs / physiology. Models, Biological. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / pathology. Neoplasm Proteins / physiology. Receptor, Epidermal Growth Factor / physiology. TNF-Related Apoptosis-Inducing Ligand / physiology. Wound Healing / physiology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20012924.001).
  • [ISSN] 1573-7233
  • [Journal-full-title] Cancer metastasis reviews
  • [ISO-abbreviation] Cancer Metastasis Rev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cadherins; 0 / FGF3 protein, human; 0 / Fibroblast Growth Factor 3; 0 / MicroRNAs; 0 / Neoplasm Proteins; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 91
  •  go-up   go-down


25. Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M: A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol; 2010 Aug;15(4):382-9
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer.
  • BACKGROUND: Zoledronic acid treatment reduces the incidence of skeletal-related events (SREs) in patients with bone metastases from breast, lung, and urologic cancers including prostate and renal cancer.
  • The aim of this study was to evaluate the effect of zoledronic acid on SREs in patients with bone metastases from bladder cancer.
  • PATIENTS AND METHODS: Patients with bone metastases from bladder cancer who were receiving palliative radiotherapy were randomized to placebo or zoledronic acid (4 mg intravenous monthly) for 6 months.
  • CONCLUSIONS: Zoledronic acid therapy decreased the incidence of SREs and improved the 1-year survival rate of patients with bone metastases from bladder cancer, potentially through its anticancer activity.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Bone Density Conservation Agents / administration & dosage. Bone Neoplasms / drug therapy. Diphosphonates / administration & dosage. Imidazoles / administration & dosage. Urinary Bladder Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20354750.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


26. Velcheti V, Govindan R: Metastatic cancer involving bladder: a review. Can J Urol; 2007 Feb;14(1):3443-8
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic cancer involving bladder: a review.
  • PURPOSE: Bladder cancer is the fourth most common cancer in men and the ninth most common cancer in women.
  • Bladder is not a common site for metastasis of cancer and often goes undiagnosed in the clinical follow up of cancer patients.
  • We reviewed the literature for published reports on metastatic cancer involving bladder.
  • MATERIALS AND METHODS: We searched MEDLINE, PubMed and OVID from 1953 to June 2005 for published reports on metastatic cancer involving bladder.
  • They key words used were bladder, cancer and metastatic.
  • All relevant articles reporting metastatic cancer to the bladder were reviewed.
  • RESULTS: We found 264 cases of metastasis to the bladder from various primary foci.
  • CONCLUSIONS: The definitive diagnosis of metastatic bladder cancers is often difficult, and poses a significant challenge to the physician, pathologist and the radiologist alike.
  • Bladder adenocarcinomas are uncommon and any adenocarcinoma of the bladder should be viewed with a high index of suspicion for a metastatic cancer from a distant focus.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Breast Neoplasms / pathology. Canada / epidemiology. Colonic Neoplasms / pathology. Humans. Incidence. Rectal Neoplasms / pathology. Skin Neoplasms / pathology. Stomach Neoplasms / pathology. Urinary Bladder / pathology. Urinary Bladder / radiography. Urogenital Neoplasms / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17324324.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Number-of-references] 100
  •  go-up   go-down


27. Crowley RW, Sherman JH, Le BH, Jane JA Sr: Intramedullary spinal cord metastasis from bladder carcinoma: case report. Neurosurgery; 2008 Sep;63(3):E611-2; discussion E612
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intramedullary spinal cord metastasis from bladder carcinoma: case report.
  • OBJECTIVE: Intramedullary spinal cord metastases are rare complications of systemic cancer.
  • Although the majority of these metastases spread from lung cancer, they have been seen to arise from a variety of other primary sources.
  • The authors report the second known case of an intramedullary spinal cord metastatic lesion arising from primary bladder carcinoma.
  • Intraoperative pathology revealed that the lesion was metastatic in nature, and the decision was made to perform a subtotal resection.
  • Pathology later confirmed that the lesion was consistent with a less differentiated form of his bladder primary.
  • CONCLUSION: The occurrence of metastatic primary bladder cancer in the intramedullary spinal cord has been reported in the literature only once previously.
  • Despite the lack of similar cases, the acute onset of Brown-Séquard syndrome was highly suggestive of a metastatic lesion.
  • [MeSH-major] Carcinoma / diagnosis. Spinal Cord Neoplasms / diagnosis. Spinal Cord Neoplasms / secondary. Urinary Bladder Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812942.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Singh AV, Franke AA, Blackburn GL, Zhou JR: Soy phytochemicals prevent orthotopic growth and metastasis of bladder cancer in mice by alterations of cancer cell proliferation and apoptosis and tumor angiogenesis. Cancer Res; 2006 Feb 1;66(3):1851-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soy phytochemicals prevent orthotopic growth and metastasis of bladder cancer in mice by alterations of cancer cell proliferation and apoptosis and tumor angiogenesis.
  • A role of dietary bioactive components in bladder cancer prevention is biologically plausible because most substances or metabolites are excreted through the urinary tract and are consequently in direct contact with the mucosa of the bladder.
  • We first determined antigrowth activity of genistein against poorly differentiated 253J B-V human bladder cancer cells in vitro.
  • We also evaluated both genistin, which is a natural form of genistein, and the isoflavone-rich soy phytochemical concentrate (SPC) on the growth and metastasis of 253J B-V tumors in an orthotopic tumor model.
  • Mice treated with genistin and SPC had reduced final tumor weights by 56% (P < 0.05) and 52% (P < 0.05), respectively, associated with induction of tumor cell apoptosis and inhibition of tumor angiogenesis in vivo.
  • In addition, SPC treatment, but not genistin treatment, significantly inhibited lung metastases by 95% (P < 0.01) associated with significant down-regulation of NF-kappaB expression in tumor tissues and reduction of circulating insulin-like growth factor-I levels, suggesting that SPC may contain other bioactive ingredients that have antimetastatic activity.
  • The results from our studies suggest that further clinical investigation should be warranted to apply soy phytochemicals, such as SPC, as a potent prevention regimen for bladder cancer progression.
  • This orthotopic human bladder tumor model also provides a clinically relevant experimental tool for assessing potential preventive activity of other dietary components against bladder tumor growth and metastasis.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GENISTEIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 1999 Nov;54(5):823-8 [10565741.001]
  • [Cites] Biochem Pharmacol. 2005 Jan 15;69(2):307-18 [15627483.001]
  • [Cites] Prostate. 2002 Oct 1;53(2):143-53 [12242729.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Sep 25;777(1-2):45-59 [12270199.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1674-7 [12496060.001]
  • [Cites] J Nutr. 2003 Jul;133(7):2262-7 [12840190.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):800-6 [15170660.001]
  • [Cites] Int J Cancer. 2004 Nov 1;112(2):319-23 [15352046.001]
  • [Cites] Cancer Res. 1975 Nov;35(11 Pt. 2):3240-5 [1192400.001]
  • [Cites] J Urol. 1983 Dec;130(6):1083-6 [6644886.001]
  • [Cites] J Biol Chem. 1987 Apr 25;262(12):5592-5 [3106339.001]
  • [Cites] Am J Clin Nutr. 1991 Dec;54(6):1093-100 [1659780.001]
  • [Cites] Hematol Oncol Clin North Am. 1992 Feb;6(1):1-30 [1556044.001]
  • [Cites] Ann Urol (Paris). 1992;26(5):281-93 [1485797.001]
  • [Cites] Clin Chim Acta. 1993 Dec 31;223(1-2):9-22 [8143372.001]
  • [Cites] J Nutr. 1994 Jun;124(6):825-32 [8207540.001]
  • [Cites] Nutr Cancer. 1994;21(2):113-31 [8058523.001]
  • [Cites] J Steroid Biochem Mol Biol. 1995 Jan;52(1):97-103 [7857879.001]
  • [Cites] J Nutr. 1995 Mar;125(3 Suppl):733S-743S [7884559.001]
  • [Cites] J Urol. 1995 Oct;154(4):1532-8 [7658585.001]
  • [Cites] Nutr Cancer. 1995;24(1):1-12 [7491293.001]
  • [Cites] J Biol Chem. 1996 Feb 2;271(5):2746-53 [8576250.001]
  • [Cites] Hinyokika Kiyo. 1995 Dec;41(12):969-77 [8578986.001]
  • [Cites] Nutr Cancer. 1996;26(3):289-302 [8910911.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2916-21 [9230201.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5231-8 [9823337.001]
  • [Cites] Int J Cancer. 1998 Dec 9;78(6):775-82 [9833772.001]
  • [Cites] J Nutr. 1999 Sep;129(9):1628-35 [10460196.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):230-6 [10656454.001]
  • (PMID = 16452247.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK040561; United States / NCI NIH HHS / CA / R01 CA092546; None / None / / P30 DK040561-11; United States / NCI NIH HHS / CA / R03 CA112640-01; United States / NIDDK NIH HHS / DK / P30 DK040561-11; United States / NCI NIH HHS / CA / CA112640-01; United States / NCI NIH HHS / CA / R01 CA 92546; United States / NCI NIH HHS / CA / R03 CA112640; United States / NCI NIH HHS / CA / R01 CA092546-01A2; United States / NCI NIH HHS / CA / CA092546-01A2; United States / NCI NIH HHS / CA / R03 CA 112640
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / Isoflavones; 0 / NF-kappa B; 103107-01-3 / Fibroblast Growth Factor 2; 67763-96-6 / Insulin-Like Growth Factor I; DH2M523P0H / Genistein
  • [Other-IDs] NLM/ NIHMS109672; NLM/ PMC2683370
  •  go-up   go-down


29. Tsai TH, Tang SH, Chuang FP, Wu ST, Sun GH, Yu DS, Chang SY, Cha TL: Ipsilateral synchronous neoplasms of kidney presenting as acute pyelonephritis and bladder metastasis. Urology; 2009 May;73(5):1163.e9-11
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ipsilateral synchronous neoplasms of kidney presenting as acute pyelonephritis and bladder metastasis.
  • Metastatic renal cell carcinoma to the bladder, liver, and lung subsequently developed.
  • Recognition of this rare disease entity could prevent delays in diagnosis and treatment.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Pyelonephritis / diagnosis. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Acute Disease. Biopsy, Needle. Cystectomy / methods. Diagnosis, Differential. Disease Progression. Fatal Outcome. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18597832.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Remón J, Guardeño R, Badía A, Cardona T, Picaza JM, Lianes P: Blindness in a bladder cancer patient. Clin Transl Oncol; 2007 Feb;9(2):117-8
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blindness in a bladder cancer patient.
  • Blindness is an unusual symptom in the clinical course of cancer.
  • Brain metastases in bladder cancer are extremely rare.
  • We present a deaf-and-dumb male with subacute blindness, 12 months after the diagnosis of a metastatic bladder cancer.
  • Computerised tomography scan and MRI revealed a mass into the pituitary gland and sella, probably of metastatic origin.
  • [MeSH-major] Blindness / etiology. Carcinoma, Transitional Cell / complications. Carcinoma, Transitional Cell / secondary. Pituitary Neoplasms / complications. Pituitary Neoplasms / secondary. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Blindness.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17329224.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


31. Toledano H, Visée C, Arroua F, Rossi D, Bastide C: [Bladder metastasis of malignant melanoma: a case report and review of literature]. Prog Urol; 2009 Feb;19(2):139-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder metastasis of malignant melanoma: a case report and review of literature].
  • [Transliterated title] Métastases endovésicales de mélanome malin cutané : à propos d'un cas et revue de la littérature.
  • Metastatic malignant melanoma to the urinary bladder remains rare in clinical practice with less than 10 cases reported in the last 30 years in the literature.
  • [MeSH-major] Melanoma / secondary. Skin Neoplasms / pathology. Urinary Bladder Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19168020.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 6
  •  go-up   go-down


32. Frachet O, Cordier G, Henry N, Tligui M, Gattegno B, Sebe P: [Bladder perforation during transurethral resection of bladder tumour: a review]. Prog Urol; 2007 Nov;17(7):1310-2
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder perforation during transurethral resection of bladder tumour: a review].
  • [Transliterated title] Perforations vésicales au cours d'une résection trans-uréthrale de tumeur de vessie.
  • Transurethral resection of bladder tumour is a common procedure (10,711 new cases of bladder tumour diagnosed in France in 2000), associated with a certain morbidity.
  • Intra- or extraperitoneal perforation of the bladder wall is a possible complication.
  • The diagnosis is generally established intraoperatively and cystography can be performed in the operating room to demonstrate the diameter of the perforation.
  • Most cases of extraperitoneal perforation can be treated conservatively by simple bladder drainage.
  • One of the risks of perforation is also tumour seeding outside of the bladder However metastases related to perforation appear to be rare and occur rapidly requiring close surveillance.
  • [MeSH-major] Intraoperative Complications / etiology. Urinary Bladder / injuries. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18271412.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 20
  •  go-up   go-down


33. Shirakawa H, Kozakai N, Sugiura H, Hara S: [Urinary bladder metastasis of prostate cancer : a case report]. Hinyokika Kiyo; 2010 Feb;56(2):123-5
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urinary bladder metastasis of prostate cancer : a case report].
  • The transrectal ultrasonography guided biopsy of the prostate revealed prostate cancer.
  • Computed tomography, magnetic resonance imaging (MRI) and bone scintigraphy showed multiple metastases to his bones and lymph nodes.
  • The MRI incidentally revealed a solitary tumor at the right lateral wall of the urinary bladder.
  • Transurethral resection of the bladder tumor was performed, and histopathological examination showed the bladder tumor composed of not urothelial carcinoma but metastatic adenocarcinoma from prostate cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / secondary

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20186001.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


34. Blasberg JD, Schwartz G, Mull JA, Moore E: Isolated bladder metastasis causing large bowel obstruction: a case report of an atypical presentation of intussusception. Cases J; 2009;2:7124

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated bladder metastasis causing large bowel obstruction: a case report of an atypical presentation of intussusception.
  • In adults, this pathology is usually associated with a malignant lead point and often requires operative management.
  • Reported is the case of an 83-year-old female who was recently diagnosed with superficial bladder cancer (T1) treated by partial cystectomy.
  • She presented 3 months post-operatively with an isolated mucosal metastasis of the transverse colon causing intussusception and large bowel obstruction.
  • Histology was significant for a pedunculated sarcomatoid bladder carcinoma originating from the colonic mucosa with incomplete invasion of the bowel wall.
  • An isolated mucosal metastasis of this variety has not been reported in the literature to date.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2009 Jan;73(1):210.e3-5 [18372021.001]
  • [Cites] Urol Int. 1999;62(2):69-75 [10461106.001]
  • [Cites] J Urol. 1998 May;159(5):1497-503 [9554341.001]
  • [Cites] Int J Urol. 2002 Jun;9(6):354-8 [12110101.001]
  • [Cites] Am J Surg. 1997 Feb;173(2):88-94 [9074370.001]
  • [Cites] Am J Surg Pathol. 1994 Mar;18(3):241-9 [7509574.001]
  • [Cites] Am J Surg. 2003 Jul;186(1):75-6 [12842754.001]
  • [Cites] Ann Surg. 1997 Aug;226(2):134-8 [9296505.001]
  • (PMID = 19829915.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2740015
  •  go-up   go-down


35. Khan S, Win Z, Lloyd CR, Neriman D, Szyszko TA, Svensson WE, Al-Nahhas A: Acrometastasis to the foot: an unusual presentation of transitional cell carcinoma of the bladder. Nucl Med Rev Cent East Eur; 2007;10(1):26-8
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acrometastasis to the foot: an unusual presentation of transitional cell carcinoma of the bladder.
  • Metastases from bladder cancer to the bones of the hands or feet are rare and usually present after the diagnosis of the primary lesion has been made.
  • Subsequent bone scan revealed multiple bony metastases and hydronephrosis raising the possibility of a primary bladder tumour that was later confirmed by urine cytology and fine needle aspiration of the foot.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Carcinoma, Transitional Cell / radionuclide imaging. Carcinoma, Transitional Cell / secondary. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17694499.001).
  • [ISSN] 1506-9680
  • [Journal-full-title] Nuclear medicine review. Central & Eastern Europe
  • [ISO-abbreviation] Nucl Med Rev Cent East Eur
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 72945-61-0 / technetium Tc 99m hydroxymethylene diphosphonate; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


36. Quek ML, Flanigan RC: The role of lymph node density in bladder cancer prognostication. World J Urol; 2009 Feb;27(1):27-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of lymph node density in bladder cancer prognostication.
  • Pelvic lymph node metastases from bladder cancer occur in about 25% of patients undergoing radical cystectomy.
  • While the majority of patients with lymph node metastases will develop progressive disease, some patients do exhibit long-term survival with and without adjuvant chemotherapy.
  • The concept of lymph node density has been proposed as a means to stratify patient prognosis since it takes into account two important factors-the number of positive nodes (tumor burden) and the total number of nodes removed/examined (extent of dissection).
  • We review the literature regarding the role of lymph node density in the prognostic stratification of node-positive bladder cancer.
  • [MeSH-major] Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Humans. Lymphatic Metastasis / pathology. Prognosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19020882.001).
  • [ISSN] 1433-8726
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 35
  •  go-up   go-down


37. Nishimoto K, Oyama M, Ando T, Nakajima Y, Kiguchi H: [Inguinal lymph node metastasis of bladder carcinoma ten years after cystourethrectomy: a case report]. Hinyokika Kiyo; 2005 Nov;51(11):759-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inguinal lymph node metastasis of bladder carcinoma ten years after cystourethrectomy: a case report].
  • A 79-year-old man had undergone radical cystourethrectomy for bladder carcinoma in January, 1989.
  • Left inguinal lymph node metastases appeared again in January, 2001.
  • Chest X-ray films showed multiple lung metastases in March, 2001.
  • Papillary tumor was observed at external urethral meatus in September, 2002 and the biopsied specimens showed TCC, G1 > G2, pathologically.
  • It is suggested that the recurrent TCC tumor in the urethral remnants might metastasize into the inguinal lymph nodes.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy. Lymph Nodes / pathology. Urethra / surgery. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Humans. Inguinal Canal. Lymphatic Metastasis. Male. Time Factors

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16363710.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


38. Walvekar RR, Pantvaidya GH, Desai SB, Chaukar DA, D'Cruz AK: Urinary bladder metastasis--an unusual presentation of distant spread from a primary pyriform sinus cancer: a case report. Auris Nasus Larynx; 2006 Dec;33(4):493-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary bladder metastasis--an unusual presentation of distant spread from a primary pyriform sinus cancer: a case report.
  • Hypopharyngeal cancers have a high propensity to distant metastasis.
  • However, metastasis to the urinary bladder as an initial presentation of distant spread has not been reported in literature.
  • We present a report of a patient with a treated and controlled pyriform sinus cancer who presented with complaints of dysuria, 8 months after completion of treatment.
  • Cystoscopy revealed a bladder mass and biopsy confirmed it to be a metastatic squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Hypopharyngeal Neoplasms / pathology. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Adult. Bone Neoplasms / secondary. Cystoscopy. Fatal Outcome. Humans. Male. Neck Dissection. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Sinus cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16920307.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


39. Offret H, Porras J, Offret O, Labetoulle M, Fabre M: [Eyelid metastasis from a bladder urothelial carcinoma]. J Fr Ophtalmol; 2007 Oct;30(8):861-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Eyelid metastasis from a bladder urothelial carcinoma].
  • [Transliterated title] Métastase conjonctivo-palpébrale d'un cancer de la vessie.
  • INTRODUCTION: Case report of an eyelid metastasis from a bladder urothelial carcinoma.
  • OBSERVATION: A 71-year-old man presented with an eyelid metastasis.
  • The patient had had a bladder carcinoma (pT1HG-2) resected 3 years before.
  • Histologic patterns of bone and eyelid metastases were consistent with a high-grade urothelial carcinoma (pT1HG-2).
  • In this case, eyelid metastasis was an incidental finding of end-stage disseminated metastatic spread of the tumor.
  • CONCLUSION: Eyelid metastases of the bladder are infrequent and associated with disseminated metastatic spread of the tumor.
  • [MeSH-major] Eyelid Neoplasms / secondary. Neoplasm Metastasis / pathology. Urinary Bladder Neoplasms / pathology. Urothelium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17978686.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


40. Rades D, Meyners T, Veninga T, Stalpers LJ, Schild SE: Hypofractionated whole-brain radiotherapy for multiple brain metastases from transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys; 2010 Oct 1;78(2):404-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofractionated whole-brain radiotherapy for multiple brain metastases from transitional cell carcinoma of the bladder.
  • PURPOSE: Brain metastases in bladder cancer patients are extremely rare.
  • Because its radiosensitivity is relatively low, metastases from bladder cancer may be treated better with hypofractionated radiotherapy.
  • METHODS AND MATERIALS: Data for 33 patients receiving WBRT alone for multiple brain metastases from transitional cell bladder carcinoma were retrospectively analyzed.
  • Five additional potential prognostic factors were investigated: age, gender, Karnofsky performance score (KPS), number of brain metastases, and extracranial metastases.
  • On univariate analysis, improved OS was associated with less than four brain metastases (p = 0.021) and almost associated with a lack of extracranial metastases (p = 0.057).
  • CONCLUSIONS: Short-course WBRT with 5 × 4 Gy should be seriously considered for most patients with multiple brain metastases from bladder cancer, as it resulted in improved LC.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Carcinoma, Transitional Cell / radiotherapy. Cranial Irradiation / methods. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20171794.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Shen CH, Shee JJ, Wu JY, Lin YW, Wu JD, Liu YW: Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model. Br J Pharmacol; 2010 Aug;160(8):2008-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model.
  • BACKGROUND AND PURPOSE: Bladder cancer is a highly recurrent cancer after intravesical therapy, so new drugs are needed to treat this cancer.
  • Hence, we investigated the anti-cancer activity of combretastatin A-4 (CA-4), an anti-tubulin agent, in human bladder cancer cells and in a murine orthotopic bladder tumour model.
  • The effect of intravesical CA-4 therapy on the development of tumours was studied in the murine orthotopic bladder tumour model.
  • Cytotoxic IC(50) values of CA-4 in human bladder cancer cells were below 4 nM.
  • The analyses of apoptosis showed that CA-4 induced caspase-3 activation and decreased BubR1 and Bub3 in cancer cells.
  • Importantly, the in vivo study revealed that intravesical CA-4 therapy retarded the development of murine bladder tumours.
  • CONCLUSIONS AND IMPLICATIONS: These data demonstrate that CA-4 kills bladder cancer cells by inducing apoptosis and mitotic catastrophe.
  • It inhibited cell migration in vitro and tumour growth in vivo.
  • Hence, CA-4 intravesical therapy could provide another strategy for treating superficial bladder cancers.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Cell Proliferation / drug effects. Stilbenes / pharmacology. Tubulin Modulators / pharmacology. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line, Tumor. Cell Movement / drug effects. Dose-Response Relationship, Drug. Female. Humans. Inhibitory Concentration 50. Mice. Mice, Inbred C57BL. Microtubules / drug effects. Microtubules / metabolism. Neoplasm Invasiveness. Phosphorylation. Proto-Oncogene Proteins c-akt / metabolism. Time Factors. Tumor Burden / drug effects

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5287-97 [19738110.001]
  • [Cites] Cell Cycle. 2009 Oct 1;8(19):3172-81 [19755861.001]
  • [Cites] Genes Dev. 2001 Jan 1;15(1):1-14 [11156599.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 [16493418.001]
  • [Cites] Curr Probl Cancer. 2001 Jul-Aug;25(4):219-78 [11514784.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2735-41 [12171907.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Sep;43(3):277-86 [12270783.001]
  • [Cites] J Med Chem. 2006 Jun 1;49(11):3143-52 [16722633.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jun;130(6):844-52 [16740038.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3075-80 [16809732.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 [12516034.001]
  • [Cites] Apoptosis. 2003 Oct;8(5):413-50 [12975575.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4428-38 [14645433.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):96-100 [14734457.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2825-37 [15077146.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4621-8 [15231674.001]
  • [Cites] Am J Pathol. 2004 Oct;165(4):1401-11 [15466404.001]
  • [Cites] Cancer. 1982 Mar 1;49(5):1056-66 [7037151.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 May;80(10):2926-30 [6574461.001]
  • [Cites] J Surg Oncol. 1988 Mar;37(3):177-84 [3352272.001]
  • [Cites] Experientia. 1989 Feb 15;45(2):209-11 [2920809.001]
  • [Cites] J Med Chem. 1995 May 12;38(10):1666-72 [7752190.001]
  • [Cites] Anticancer Drug Des. 1995 Jun;10(4):299-309 [7786396.001]
  • [Cites] Mol Carcinog. 1995 Jul;13(3):173-81 [7619220.001]
  • [Cites] Cancer Res. 1997 May 15;57(10):1829-34 [9157969.001]
  • [Cites] J Cell Sci. 1997 Sep;110 ( Pt 17):2013-25 [9378753.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1626-34 [10197639.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(5):355-61 [10501907.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1527-33 [15746056.001]
  • [Cites] J Clin Invest. 2005 Nov;115(11):2992-3006 [16224539.001]
  • [Cites] J Biol Chem. 2000 Nov 3;275(44):34710-8 [10942766.001]
  • [Cites] BMC Cancer. 2006;6:280 [17156434.001]
  • [Cites] Mol Cancer Ther. 2006 Dec;5(12):3209-21 [17172425.001]
  • [Cites] Apoptosis. 2007 Jan;12(1):155-66 [17143747.001]
  • [Cites] World J Urol. 2007 Jun;25(3):285-95 [17530260.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Oct;323(1):365-73 [17646428.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):623-34 [17726580.001]
  • [Cites] Mol Pharmacol. 2008 Feb;73(2):419-30 [17991869.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1951-61 [18024794.001]
  • [Cites] Curr Opin Oncol. 2008 May;20(3):307-14 [18391631.001]
  • [Cites] Int Braz J Urol. 2008 Mar-Apr;34(2):220-6; discussion 226-9 [18462521.001]
  • [Cites] Expert Opin Pharmacother. 2008 Oct;9(15):2603-16 [18803448.001]
  • [Cites] Cancer Treat Rev. 2008 Dec;34(8):737-49 [18722718.001]
  • [Cites] Nat Rev Drug Discov. 2008 Dec;7(12):1013-30 [19043451.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2008 Sep;(218):12-20 [19054893.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Cell Cycle. 2006 Mar;5(6):603-5 [16582622.001]
  • (PMID = 20649598.001).
  • [ISSN] 1476-5381
  • [Journal-full-title] British journal of pharmacology
  • [ISO-abbreviation] Br. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Stilbenes; 0 / Tubulin Modulators; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; I5590ES2QZ / fosbretabulin
  • [Other-IDs] NLM/ PMC2958646
  •  go-up   go-down


42. Raspollini MR, Comin CE, Crisci A, Chilosi M: The use of placental S100 (S100P), GATA3 and napsin A in the differential diagnosis of primary adenocarcinoma of the bladder and bladder metastasis from adenocarcinoma of the lung. Pathologica; 2010 Feb;102(1):33-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of placental S100 (S100P), GATA3 and napsin A in the differential diagnosis of primary adenocarcinoma of the bladder and bladder metastasis from adenocarcinoma of the lung.
  • Primary bladder adenocarcinoma accounts for 0.5-2% of all malignant bladder tumours.
  • Literature data indicate the bladder as the second most common site of metastatic genitourinary tumours, with the kidney as the most frequent location.
  • Secondary tumours of the bladder account for about 2.3% of all bladder malignancies encountered in surgical specimens.
  • Herein, we describe an adenocarcinoma deeply infiltrating the bladder wall, with no morphologic features of transitional cell carcinoma, in a patient with a previous diagnosis of primary lung adenocarcinoma, mixed subtype.
  • In this case, the use of a limited immunohistochemical panel including napsin A, a recently described highly sensitive marker for lung adenocarcinoma, GATA3 and S100P, two novel markers of urothelial differentiation, was of crucial importance in differentiating between lung adenocarcinoma metastatic to the bladder and primary bladder adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Aspartic Acid Endopeptidases / metabolism. Biomarkers, Tumor / metabolism. GATA3 Transcription Factor / metabolism. Lung Neoplasms. S100 Proteins / metabolism. Urinary Bladder Neoplasms

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20731252.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GATA3 Transcription Factor; 0 / GATA3 protein, human; 0 / S100 Proteins; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.- / NAPSA protein, human
  •  go-up   go-down


43. Ma Y, Hou Y, Liu B, Li X, Yang S, Ma J: Intratumoral lymphatics and lymphatic vessel invasion detected by D2-40 are essential for lymph node metastasis in bladder transitional cell carcinoma. Anat Rec (Hoboken); 2010 Nov;293(11):1847-54
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoral lymphatics and lymphatic vessel invasion detected by D2-40 are essential for lymph node metastasis in bladder transitional cell carcinoma.
  • Bladder cancer is frequently associated with regional lymph node metastasis at the time of diagnosis or after initial treatment, and lymph node metastasis is crucial for clinical therapeutic strategies.
  • Lymphangiogenesis, detected by antibodies specific for lymphatic endothelial cells, is correlated with cancer spread, but the mechanisms that underlie lymphatic spread and the role of lymphangiogenesis in cancer metastasis has been less clear.
  • The aim of this study was to investigate the association of vascular endothelial growth factor (VEGF)-D expression, intratumoral lymphatics, and lymphatic invasion associated with lymph node metastasis as well as the prognostic analysis in patients with bladder transitional cell carcinoma (TCC).
  • The high expression of VEGF-D was closely associated with the intratumoral lymphatic vessels, tumoral lymphatic invasion, and lymph node metastasis as well as a shorter overall survival.
  • Higher lymphatic vessel density, intratumoral lymphatics, and lymphatic invasion showed a significant association with lymph node metastasis.
  • Univariate analysis indicated that VEGF-D, intratumoral lymphatics, and lymphatic invasion were associated with overall survival, but they were not independent prognostic factors for bladder TCC in multivariate analysis.
  • Intratumoral lymphatics and lymphatic invasion are important predictive factors of pelvic lymph node metastasis in patients with bladder cancer.
  • [MeSH-major] Antibodies, Monoclonal. Carcinoma, Transitional Cell / pathology. Lymph Nodes / pathology. Lymphatic Metastasis / diagnosis. Lymphatic Vessels / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Biomarkers, Tumor / metabolism. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness / pathology. Prognosis. Retrospective Studies. Survival Rate. Vascular Endothelial Growth Factor D / metabolism

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20730866.001).
  • [ISSN] 1932-8494
  • [Journal-full-title] Anatomical record (Hoboken, N.J. : 2007)
  • [ISO-abbreviation] Anat Rec (Hoboken)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor D; 0 / monoclonal antibody D2-40
  •  go-up   go-down


44. Kagota M, Irie K, Hosaka K, Takezaki T: Bladder metastasis of renal cell carcinoma; a case study. Hinyokika Kiyo; 2007 Aug;53(8):571-4
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder metastasis of renal cell carcinoma; a case study.
  • Multiple lung metastases were observed, and immunotherapy using IFN-alpha was introduced after the operation.
  • Gross hematuria was seen 1 year after the operation, and cystoscopy revealed a submucosal tumor in the bladder.
  • Transurethral resection of the tumor was performed, and pathological diagnosis was metastasis from the RCC.
  • Six months later, he died because of multiple metastases of the tumor.
  • Thirty cases of metastasis of RCC to the bladder, including our case, have been reported in Japan.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Aged. Humans. Immunotherapy. Interferon-alpha / therapeutic use. Lung Neoplasms / secondary. Male

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17874550.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interferon-alpha
  •  go-up   go-down


45. Kanoh T, Nakano Y, Inatome J, Sakamoto T, Kira T, Miyazaki S, Danno K, Kimura Y, Iwazawa T, Ohnishi T, Tono T, Yano H, Monden T, Imaoka S: [A case of successfully treated orbital metastasis from breast cancer by radiation therapy]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2231-3
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of successfully treated orbital metastasis from breast cancer by radiation therapy].
  • Orbital metastasis from breast cancer is relatively rare.
  • We report a case of successfully treated orbital metastasis from breast cancer by radiation therapy.
  • The diagnosis was invasive lobular carcinoma, Stage IIB (T2N1M0).
  • Retroperitoneal and bladder metastases were found five years after the operation, and chemohormonal therapy was done.
  • Right orbital swelling appeared 8 months after chemohormonal therapy, and orbital metastasis from breast cancer was diagnosed by MRI.
  • An MRI was performed 16 months after radiation therapy and did not detect any metastases.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Mastectomy. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Metastasis / radiotherapy. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106580.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


46. Saad F, Eastham JA: Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer. Semin Oncol; 2010 Jun;37 Suppl 1:S38-44
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer.
  • Approximately 30% of patients with renal cell carcinoma (RCC) and 40% of patients with bladder cancer develop bone metastases that can disrupt normal bone homeostasis and place patients at risk for potentially life-limiting skeletal-related events (SREs).
  • In patients with bone metastases from RCC or bladder cancer, zoledronic acid (ZOL) significantly reduced the risk of SREs compared with placebo.
  • In addition to its bone-protective effects, preclinical and early clinical evidence indicates that ZOL prevents tumor progression.
  • Additionally, a study in patients with bone metastases from bladder cancer demonstrated that ZOL improved 1-year overall survival compared with placebo.
  • Bone metastases place a heavy burden on patients with RCC or bladder cancer, and early, continuous treatment with ZOL may provide anticancer benefits in addition to important patient quality of life.
  • [MeSH-major] Bone Neoplasms / prevention & control. Carcinoma, Renal Cell / drug therapy. Diphosphonates / therapeutic use. Imidazoles / therapeutic use. Kidney Neoplasms / drug therapy. Urinary Bladder Neoplasms / drug therapy


47. Richter C, Baetje M, Bischof A, Makovitzky J, Richter DU, Gerber B, Briese V: Expression of the glycodelin A gene and the detection of its protein in tissues and serum of ovarian carcinoma patients. Anticancer Res; 2007 Jul-Aug;27(4A):2023-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is suspected to be a marker of human ovarian cancer tissues.
  • MATERIALS AND METHODS: We investigated serum, tissue and cyst fluid samples of patients with an ovarian carcinoma in contrast to patients with benign and malignant diseases such as uterine myoma, endometriosis, cervical, uterine and breast cancer, and metastases of bladder and colon carcinoma.
  • CONCLUSION: These results indicate that determination of GdA is not sensitive or specific enough for use as a tumour marker.
  • [MeSH-major] Biomarkers, Tumor / analysis. Gene Expression. Glycoproteins / biosynthesis. Ovarian Neoplasms / diagnosis. Pregnancy Proteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649816.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / PAEP protein, human; 0 / Pregnancy Proteins; 0 / RNA, Messenger
  •  go-up   go-down


48. Hatano K, Kawashima A, Arai Y, Inoue H, Miyagawa Y, Takaha N, Nishimura K, Miyake O, Okuyama A: [Pelvic lymph node metastasis from bladder cancer markedly responsive to methotrexate vinblastine doxorubicin and cisplatin (M-VAC) therapy followed by radiotherapy: a case report]. Hinyokika Kiyo; 2006 Oct;52(10):801-3
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pelvic lymph node metastasis from bladder cancer markedly responsive to methotrexate vinblastine doxorubicin and cisplatin (M-VAC) therapy followed by radiotherapy: a case report].
  • We report a case of bladder cancer with pelvic lymph node metastasis effectively treated by chemotherapy followed by radiotherapy.
  • After 31 months, computerized tomography (CT) revealed a bulky tumor (7.0 x 5.6 cm) along the left pelvic wall, indicating pelvic lymph node metastasis.
  • Five courses of chemotherapy consisting of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) was performed.
  • The size of the tumor was reduced to 1.5 x 1.0 cm.
  • Then, external beam radiotherapy (50 Gy) was added to the residual tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / radiotherapy. Lymph Nodes / pathology. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Humans. Lymphatic Metastasis. Male. Methotrexate / administration & dosage. Pelvis. Radiotherapy Dosage. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17131872.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


49. Lin HC, Chang CH, Li WM, Hsiao HL, Chang TH, Wu WJ, Huang CH: Orbital metastasis from urothelial carcinoma of the urinary bladder. Kaohsiung J Med Sci; 2007 Feb;23(2):84-8
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital metastasis from urothelial carcinoma of the urinary bladder.
  • Radical cystectomy with ileal conduit diversion remains the standard treatment for invasive bladder cancer.
  • We report a patient with urothelial carcinoma of the urinary bladder and found metastasis to the orbit post radical cystectomy and ileal conduit diversion presenting as blurred vision and diagnosed by open biopsy.
  • The orbit is an infrequent site of metastasis from bladder cancer cells.
  • To the best of our knowledge, there are fewer than 10 case reports of orbital metastasis from urothelial carcinoma reported in the English medical literature.
  • [MeSH-major] Orbital Neoplasms / secondary. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Kaohsiung J Med Sci. 2007 Apr;23(4):215
  • (PMID = 17339171.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China (Republic : 1949- )
  • [Number-of-references] 15
  •  go-up   go-down


50. Matsuhashi N, Yamaguchi K, Tamura T, Shimokawa K, Sugiyama Y, Adachi Y: Adenocarcinoma in bladder diverticulum, metastatic from gastric cancer. World J Surg Oncol; 2005 Aug 24;3:55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in bladder diverticulum, metastatic from gastric cancer.
  • BACKGROUND: Metastasis to the urinary bladder from gastric cancer is rare.
  • Metastasis to a diverticulum of the bladder from gastric cancer is extremely rare.
  • We report a case of isolated bladder metastasis from gastric cancer and invasion localized to the muscularis propria of the primary site (stomach).
  • CASE PRESENTATION: A 90-year-old female presented with nausea and vomiting that was diagnosed as gastric cancer, the patient also had intermittent hematuria.
  • Pelvic computed tomography identified an abnormally thickened area in the bladder wall that was diagnosed as a diverticulum of the bladder.
  • A biopsy of the bladder wall revealed well differentiated tubular adenocarcinoma metastatic from gastric carcinoma.
  • CONCLUSION: Almost all cases of bladder metastasis from gastric cancer had peritoneal dissemination.
  • This particular presentation of bladder metastasis from gastric cancer, to the best of our knowledge, has not been previously reported.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Clin Oncol. 1999 Jun;29(6):314-6 [10418562.001]
  • [Cites] Cancer. 1955 Jul-Aug;8(4):741-58 [13240656.001]
  • [Cites] J Urol. 1956 Jun;75(6):965-72 [13320594.001]
  • [Cites] Urology. 1992 May;39(5):464-7 [1580041.001]
  • (PMID = 16117837.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1208965
  •  go-up   go-down


51. Croft PR, Lathrop SL, Feddersen RM, Joste NE: Estrogen receptor expression in papillary urothelial carcinoma of the bladder and ovarian transitional cell carcinoma. Arch Pathol Lab Med; 2005 Feb;129(2):194-9
Hazardous Substances Data Bank. FORMALDEHYDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen receptor expression in papillary urothelial carcinoma of the bladder and ovarian transitional cell carcinoma.
  • CONTEXT: Relatively little is known about estrogen receptor (ER) expression in papillary urothelial carcinoma (PUC) of the bladder.
  • Greater understanding of this feature of PUCs could aid with the treatment and identification of the origin of metastases, particularly with relation to the morphologically similar entity of ovarian transitional cell carcinoma (TCC).
  • OBJECTIVE: To assess the presence of ERs in PUC of the bladder, its metastases, and ovarian TCC.
  • DESIGN: Formalin-fixed, paraffin-embedded archival tissue from 92 primary bladder PUCs, 11 PUC metastases, and 11 primary or metastatic ovarian TCCs was immunostained with a monoclonal antibody against the human ER beta-molecule.
  • The ER-positive and ER-negative tumors were compared by the patients' sex and age, tumor grade, and the presence or absence of invasion.
  • RESULTS: By the 10% criterion, 11% of PUCs of the bladder were ER positive.
  • All 11 PUC metastases were totally ER negative.
  • CONCLUSION: Depending on the criterion used, up to 22% of bladder PUCs were ER positive.
  • Higher grade and the presence of invasion were significantly associated with ER expression in these bladder carcinomas.
  • In contrast, almost all of the ovarian TCCs marked strongly for ERs, a characteristic that may help differentiate these lesions from PUCs metastatic to the ovary.
  • [MeSH-major] Carcinoma, Papillary / genetics. Carcinoma, Transitional Cell / genetics. Gene Expression Regulation, Neoplastic / physiology. Ovarian Neoplasms / genetics. Receptors, Estrogen / genetics. Urinary Bladder Neoplasms / genetics. Urothelium / pathology

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Arch Pathol Lab Med. 2005 Jul;129(7):852
  • (PMID = 15679420.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Estrogen Receptor beta; 0 / Receptors, Estrogen; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


52. Kuyumcuoğlu U, Kale A: Tragic results of suboptimal gynecologic cancer operations. Eur J Gynaecol Oncol; 2008;29(6):620-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tragic results of suboptimal gynecologic cancer operations.
  • OBJECTIVE: The goal of this study was to analyze gynecological cancer patients who underwent suboptimal or failed surgeries with unsatisfactory and undesired results.
  • RESULTS: Optimal cytoreduction was achieved in ten women (21.7%), 32 women (69.5%) had suboptimal surgical cytoreduction and four women (8.6%) had failed surgery, Seven patients were recurrences (3 had liver metastasis, 2 had pelvic metastasis, 2 had bladder metastasis); two patients died due to bladder metastasis, one patient died six days after surgery due to a pulmonary embolism in the suboptimal cytoreduction group, and one patient died due to ascites in the failed surgery group.
  • Optimal surgery was achieved in three women (27.2%) and eight women (72.7%) had suboptimal surgery in the cervical cancer population.
  • One patient had a recurrence with pelvic metastasis in the suboptimal group.
  • Suboptimal surgery was achieved in one woman with vulvar cancer.
  • Optimal surgery was achieved in seven women (43.7%) and nine women (56.2%) had suboptimal surgery in the endometrial cancer population.
  • The prognosis of 30 (65.2%) women in the ovarian cancer population, eight (72.7%) women in the cervical cancer group, 11 (68.7%) women in the endometrial cancer group, and one woman (100%) in the vulvar cancer population was unknown.
  • CONCLUSION: If a gynecologist does not have enough experience or expertise about gynecological cancer operations, he or she must consider the possible harm that any surgical intervention might do, as the latin phrase "primum non nocere" means and should refer patients to a gynecological oncology center without performing any surgery.
  • [MeSH-major] Genital Neoplasms, Female / surgery. Gynecologic Surgical Procedures / adverse effects. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19115691.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


53. Jamieson D, Wilson K, Pridgeon S, Margetts JP, Edmondson RJ, Leung HY, Knox R, Boddy AV: NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism. Clin Cancer Res; 2007 Mar 1;13(5):1584-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.
  • The NQO activity of ovarian and bladder tumors was determined and the effect of NQO polymorphisms on NQO activity was investigated.
  • EXPERIMENTAL DESIGN: Intraperitoneal ovarian metastases and bladder tumor clinical samples were analyzed for NQO1 and NQO2 activity, mRNA expression by semiquantitative reverse transcription-PCR, and genotype by RFLP analysis.
  • RESULTS: NQO1 activity was higher in the bladder cohort than in the ovarian cohort (0-283 and 0-30 nmol/min/mg, respectively; P < 0.0001).
  • In contrast, NQO2 activity was higher in the ovarian tissue than in the bladder samples (0.15-2.27 and 0-1.14 nmol/min/mg, respectively; P = 0.0004).
  • The NQO2 exon 3 T14055C SNP was associated with lower NQO2 activity relative to wild-type [median values of 0.18 and 0.37 nmol/min/mg in the bladder samples (P = 0.007) and 0.82 and 1.16 nmol/min/mg in the ovarian cohort (P = 0.034)].
  • The high NQO2 activity of intraperitoneal ovarian metastases relative to other tissues indicates a potential for tretazicar therapy in the treatment of this disease.
  • [MeSH-major] NAD(P)H Dehydrogenase (Quinone) / metabolism. Niacinamide / analogs & derivatives. Ovarian Neoplasms / enzymology. Quinone Reductases / metabolism. Urinary Bladder Neoplasms / enzymology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17332305.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1341-23-7 / nicotinamide-beta-riboside; 25X51I8RD4 / Niacinamide; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human; EC 1.6.99.- / NRH - quinone oxidoreductase2; EC 1.6.99.- / Quinone Reductases
  •  go-up   go-down


54. Segawa N, Azuma H, Takahara K, Hamada S, Kotake Y, Tsuji M, Katsuokai Y: [Port-site metastasis after retroperitoneoscopy-assisted nephroureterectomy and cystectomy for bladder cancer invading the ureter: a case report]. Hinyokika Kiyo; 2008 Jan;54(1):13-6
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Port-site metastasis after retroperitoneoscopy-assisted nephroureterectomy and cystectomy for bladder cancer invading the ureter: a case report].
  • We report a case of port-site metastasis of bladder cancer after left retroperitoneoscopy-assisted nephroureterectomy and cystectomy.
  • The diagnosis was invasive bladder cancer with bone metastasis.
  • He received two courses of chemotherapy (methotrexate, vinblastine, adriamycin, cisplatin), and this resulted in resolution of the bone metastases.
  • Two months later, abdominal and pelvic computed tomography showed a bladder tumor invading the left lower ureter with hydronephrosis.
  • Four months later, a lateral abdominal wall tumor was found at a port-site, and needle biopsy confirmed this to be metastatic urothelial carcinoma.
  • Clinicians need to be aware of port-site metastasis, particularly in patients with UC, and take steps to prevent it during laparoscopic procedures.
  • [MeSH-major] Abdominal Neoplasms / secondary. Carcinoma / surgery. Cystectomy. Endoscopy. Neoplasm Invasiveness. Neoplasm Seeding. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / surgery. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260354.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


55. Paick SH, Ku JH, Kwak C, Lee SE: Hand-assisted retroperitoneoscopic nephroureterectomy without hand-assisted device. J Korean Med Sci; 2005 Oct;20(5):901-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Various laparoscopic nephroureterectomy techniques for urothelial carcinoma of the upper urinary tract have been developed to minimize postoperative discomfort and the necessity for a lengthy convalescence.
  • At the average follow-up of 8.1 months, no regional recurrence, port-site metastasis, bladder recurrence, or distant metastasis were noted in any patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endourol. 1998 Aug;12(4):345-53 [9726401.001]
  • [Cites] Urology. 1998 Oct;52(4):594-601 [9763077.001]
  • [Cites] J Urol. 1999 Feb;161(2):430-4 [9915419.001]
  • [Cites] J Urol. 1999 Feb;161(2):541-4 [9915444.001]
  • [Cites] BJU Int. 1999 Mar;83(4):504-5 [10210579.001]
  • [Cites] J Urol. 2000 Apr;163(4):1100-4 [10737474.001]
  • [Cites] J Urol. 1998 Jul;160(1):22-7 [9628597.001]
  • [Cites] Urology. 2000 Nov 1;56(5):741-7 [11068291.001]
  • [Cites] BJU Int. 2000 Oct;86(6):619-23 [11069365.001]
  • [Cites] Urol Clin North Am. 2000 Nov;27(4):761-73 [11098773.001]
  • [Cites] J Urol. 2002 Jun;167(6):2387-91 [11992043.001]
  • [Cites] J Endourol. 1998 Apr;12(2):139-41 [9607440.001]
  • [Cites] J Urol. 2000 Nov;164(5):1513-22 [11025694.001]
  • (PMID = 16224173.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2779296
  •  go-up   go-down


56. Hadzi-Djokić J, Pejcić T, Aćimović M, Andrejević V, Radosavljević R: Penile metastasis from invasive bladder cancer. Acta Chir Iugosl; 2009;56(2):101-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Penile metastasis from invasive bladder cancer.
  • OBJECTIVE: To present the rare case of penile metastasis from bladder cancer.
  • PATIENT REPORT: A 68-year-old man with invasive bladder cancer disseminated in penile shaft and the pelvic lymph nodes is presented.
  • CONCLUSION: Despite the fact that secondary penile tumors usually require palliative therapy, in selected cases surgical treatment of primary tumor and penectomy, followed with chemotherapy, can improve survival.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Penile Neoplasms / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Lymphatic Metastasis. Male. Pelvis

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19780339.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


57. Kumar B, Koul S, Petersen J, Khandrika L, Hwa JS, Meacham RB, Wilson S, Koul HK: p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer Res; 2010 Jan 15;70(2):832-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity.
  • In transitional cell carcinoma, the most common form of bladder cancer, overexpression of the matrix metalloproteinases MMP-2 and MMP-9 offers prognostic value as markers of disease-specific survival.
  • These molecules have been implicated in metastasis of bladder cancer, but the underlying mechanisms through which they are controlled are poorly defined.
  • In this study, we investigated a role of p38 mitogen-activated protein kinase (MAPK) in this process, using bladder cancer cell lines HTB9 and HTB5 that were derived from different tumor stages. p38 MAPK modulated MMP-2/9 mRNA levels at the levels of transcript stability and MMP-2/9 activity along with invasive capacity.
  • Conversely, p38 MAPK inhibition blocked the MAPKAPK2-mediated increase in MMP-2/9 activities and the invasive capacity of the cancer cells.
  • Our findings implicate p38 MAPK and MAPKAPK2 in mediating bladder cancer invasion via regulation of MMP-2 and MMP-9 at the level of mRNA stability.
  • [MeSH-major] Intracellular Signaling Peptides and Proteins / metabolism. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Protein-Serine-Threonine Kinases / metabolism. Urinary Bladder Neoplasms / enzymology. p38 Mitogen-Activated Protein Kinases / metabolism
  • [MeSH-minor] Cell Growth Processes / physiology. Cell Line, Tumor. Cell Movement / physiology. Humans. Imidazoles / pharmacology. Neoplasm Invasiveness. Pyridines / pharmacology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Transfection

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20068172.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Imidazoles; 0 / Intracellular Signaling Peptides and Proteins; 0 / Pyridines; 0 / RNA, Messenger; 0 / SB 203580; EC 2.7.1.- / MAP-kinase-activated kinase 2; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


58. Ramsey J, Beckman EN, Winters JC: Breast cancer metastatic to the urinary bladder. Ochsner J; 2008;8(4):208-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer metastatic to the urinary bladder.
  • Breast cancer is common and has the potential to spread to multiple organs.
  • This article describes metastasis to the urinary bladder.
  • In most instances, breast cancer metastatic to the bladder is associated with other pelvic organ metastasis.
  • In patients with known metastatic breast cancer, bladder screening is not warranted.
  • However, if lower urinary tract symptoms persist, an evaluation of the bladder should be considered to rule out metastatic involvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 1999;10(1):39-42 [10207766.001]
  • [Cites] Br J Cancer. 1973 Apr;27(4):336-40 [4701705.001]
  • [Cites] J Urol. 1955 Oct;74(4):498-521 [13264313.001]
  • [Cites] Cancer. 1950 Jan;3(1):74-85 [15405683.001]
  • [Cites] Int J Tissue React. 1991;13(3):159-63 [1660044.001]
  • [Cites] Cancer. 1980 Jul 1;46(1):162-7 [7388758.001]
  • [Cites] Cancer. 1980 Jul 1;46(1):229-32 [7388764.001]
  • [Cites] Acta Urol Belg. 1982 Jan;50(1):87-90 [7080990.001]
  • [Cites] J Urol. 1956 Jun;75(6):965-72 [13320594.001]
  • [Cites] J Urol. 1992 Jan;147(1):137-9 [1729507.001]
  • [Cites] Br J Urol. 1992 Jan;69(1):97-8 [1737264.001]
  • [Cites] Urology. 1987 May;29(5):544-7 [3554697.001]
  • [Cites] Surg Gynecol Obstet. 1965 Oct;121(4):813-8 [5838289.001]
  • [Cites] Int Urol Nephrol. 1995;27(3):297-300 [7591593.001]
  • [Cites] J Urol. 1970 Dec;104(6):839-42 [5532912.001]
  • [Cites] J Urol. 1951 Jan;65(1):144-53 [14804776.001]
  • [Cites] J Urol. 2001 Mar;165(3):905 [11176504.001]
  • (PMID = 21603504.001).
  • [ISSN] 1524-5012
  • [Journal-full-title] The Ochsner journal
  • [ISO-abbreviation] Ochsner J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3096370
  • [Keywords] NOTNLM ; Bladder / bladder tumor / breast / hematuria / incontinence / metastasis
  •  go-up   go-down


59. Solini A, Gargiulo G, Fronda G, De Paolis P, Ruggieri N, Garino M: Emisacrectomy, experience in 11 cases. Eur Spine J; 2009 Jun;18 Suppl 1:109-14
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Authors report their experience in 11 cases affected by tumours of the sacrum (9 chordomas, 1 ependymoma, 1 monostotic bladder metastasis) operated on at the Orthopaedic Department of A.S.O S.
  • [MeSH-minor] Aged. Carcinoma / secondary. Carcinoma / surgery. Chordoma / pathology. Chordoma / radiography. Chordoma / surgery. Ependymoma / pathology. Ependymoma / radiography. Ependymoma / surgery. Female. Follow-Up Studies. Humans. Lumbosacral Plexus / pathology. Lumbosacral Plexus / surgery. Magnetic Resonance Imaging. Male. Middle Aged. Postoperative Complications / etiology. Postoperative Complications / pathology. Postoperative Complications / physiopathology. Preoperative Care. Reconstructive Surgical Procedures / methods. Retrospective Studies. Time. Treatment Outcome. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Spine (Phila Pa 1976). 2001 Feb 15;26(4):431-9 [11224892.001]
  • [Cites] Colorectal Dis. 2009 Jun;11(5):508-12 [18637929.001]
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):36-9 [11953593.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1 Suppl):98-101 [12120660.001]
  • [Cites] J Orthop Sci. 2002;7(6):658-64 [12486469.001]
  • [Cites] J R Soc Med. 2003 Jan;96(1):28-30 [12519800.001]
  • [Cites] Spine (Phila Pa 1976). 2003 Jul 15;28(14):1567-72 [12865846.001]
  • [Cites] Hernia. 2003 Dec;7(4):224-6 [12884083.001]
  • [Cites] Neurosurg Focus. 2003 Nov 15;15(5):E9 [15323466.001]
  • [Cites] Spine (Phila Pa 1976). 1978 Dec;3(4):351-66 [741243.001]
  • [Cites] J Bone Joint Surg Br. 1987 Aug;69(4):565-8 [3611160.001]
  • [Cites] Spine (Phila Pa 1976). 1990 Nov;15(11):1223-7 [2267620.001]
  • [Cites] Langenbecks Arch Surg. 2005 Jun;390(3):255-8 [15580523.001]
  • [Cites] J Neurosurg Spine. 2005 Aug;3(2):106-10 [16370299.001]
  • [Cites] J Neurosurg Spine. 2005 Aug;3(2):111-22 [16370300.001]
  • [Cites] Ann Plast Surg. 2006 May;56(5):526-30; discussion 530-1 [16641629.001]
  • [Cites] Clin Orthop Relat Res. 2006 Sep;450:82-8 [16906087.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):390-5 [17063304.001]
  • [Cites] Arch Orthop Trauma Surg. 2002 Apr;122(3):148-55 [11927996.001]
  • (PMID = 19468760.001).
  • [ISSN] 1432-0932
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2899608
  •  go-up   go-down


60. Nakayama T, Yoshida S, Fujii Y, Koga F, Saito K, Masuda H, Kobayashi T, Kawakami S, Kihara K: [Use of diffusion-weighted MRI in monitoring response of lymph node metastatic bladder cancer treated with chemotherary]. Nihon Hinyokika Gakkai Zasshi; 2008 Nov;99(7):737-41
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of diffusion-weighted MRI in monitoring response of lymph node metastatic bladder cancer treated with chemotherary].
  • We report a case in which treatment response to lymph node metastatic bladder cancer was monitored by DW-MRI.
  • A 67-year-old man had paraaortic lymph node metastasis from bladder cancer; the paraaortic lymph node showed high signal intensity on DW-MRI.
  • These signal changes were consistent with the change of morphological images (CT, MRI (T1-W, T2-W)), 18F-FDG PET and tumor markers.
  • This case suggests that DW-MRI is useful in monitoring treatment response of metastatic bladder cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diffusion Magnetic Resonance Imaging. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Lymphatic Metastasis. Male

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068691.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


61. Monzó JI, Herranz Amo F, Cabello Benavente R, Hernández Fernández C: [The usefulness of pelvic lymphadenectomy in bladder cancer]. Actas Urol Esp; 2007 Jan;31(1):1-6
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The usefulness of pelvic lymphadenectomy in bladder cancer].
  • [Transliterated title] Utilidad de la linfadenectomía en el cáncer de vejiga. Revisión de la literatura.
  • OBJECTIVE: [corrected] To assess the usefulness of pelvic lymphadenectomy in bladder cancer.
  • METHODS AND RESULTS: With the followings key words: "bladder cancer, lymphadenectomy, lymph node metastasis" we search in Medline/PubMed database for papers published during the last ten years.
  • Nodal metastasis in bladder cancer after radical cystectomy and pelvic lymphadenectomy ranged between 18% and 28%.
  • Standard lymphadenectomy could improve tumor staging and probably survival in selected patients.
  • It is advisable to perform separate lymph node dissection rather than en-bloc.
  • [MeSH-major] Lymph Node Excision. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410978.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 33
  •  go-up   go-down


62. Eccles SA: Metastasis and the Tumor Microenvironment: A Joint Metastasis Research Society-AACR Conference - Research on Metastasis: part 2. IDrugs; 2010 Nov;13(11):768-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis and the Tumor Microenvironment: A Joint Metastasis Research Society-AACR Conference - Research on Metastasis: part 2.
  • The Metastasis and the Tumor Microenvironment Conference, held in Philadelphia, included topics covering new research developments in the field of metastasis and tumor microenvironment.
  • This conference report highlights selected presentations on translation targets from a clinical perspective, antibody inhibitors of TGFβ for metastasis suppression, metastasis in bladder and lung cancer, c-ErbB2/HER2 expression in ductal carcinomas in situ and breast cancer, targeting Hsp90 chaperones in solid cancers, peritoneal carcinomas, and the discovery and exploitation of RANK ligands in bone metastasis.
  • [MeSH-minor] Animals. Drug Delivery Systems. Drugs, Investigational / pharmacology. Humans. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21046523.001).
  • [ISSN] 2040-3410
  • [Journal-full-title] IDrugs : the investigational drugs journal
  • [ISO-abbreviation] IDrugs
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Investigational
  •  go-up   go-down


63. Zennami K, Yamada Y, Nakamura K, Aoki S, Taki T, Honda N: Solitary brain metastasis from pT1, G3 bladder cancer. Int J Urol; 2008 Jan;15(1):96-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary brain metastasis from pT1, G3 bladder cancer.
  • Brain metastasis from bladder cancer occurs rarely.
  • Particularly, solitary brain metastasis is very rare in patients who have never received systemic chemotherapy.
  • We encountered a patient who underwent transurethral resection of bladder tumor and bacillus Calmette-Guérin bladder instillation for pT1, G3 bladder cancer accompanied by carcinoma in situ, and subsequently revealed solitary brain metastasis after 34 months while neither cystoscopy nor urine cytology revealed abnormalities during this period.
  • To our knowledge, our experience of solitary brain metastasis from pT1 bladder cancer is the second case in the world.
  • [MeSH-major] Brain Neoplasms / secondary. Parietal Lobe. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18184184.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


64. Kaneko G, Kikuchi E, Hasegawa M, Miyajima A, Nakagawa K, Kameyama K, Oya M: Non-muscle invasive bladder cancer with concomitant vaginal urothelial carcinoma: a case report and review of the literature. Int J Clin Oncol; 2010 Dec;15(6):626-30
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-muscle invasive bladder cancer with concomitant vaginal urothelial carcinoma: a case report and review of the literature.
  • A 74-year-old female was referred to our hospital for non-muscle invasive bladder tumors initially treated at another hospital.
  • Preoperatively, computed tomography and magnetic resonance imaging demonstrated non-muscle invasive bladder tumors and a vaginal tumor.
  • A second transurethral resection of the bladder tumors, transvaginal tumor resection, and systemic chemotherapy were performed.
  • The pathogenesis of the vaginal UC was considered to be the primary UC or metastasis from the bladder UC.
  • [MeSH-major] Carcinoma, Papillary / secondary. Neoplasms, Multiple Primary / pathology. Urinary Bladder Neoplasms / pathology. Vaginal Neoplasms / secondary

  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20544250.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


65. Liepe K, Brogsitter C, Leonhard J, Wunderlich G, Hliscs R, Pinkert J, Folprecht G, Kotzerke J: Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization. Jpn J Clin Oncol; 2007 Dec;37(12):942-50
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients with unresectable colorectal liver metastases or hepatocellular cancer (HCC) received single treatments with (188)Re-microspheres.
  • From post-therapeutic scans and urine sampling, the dose to the liver, metastases and bladder was calculated.
  • CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.
  • RESULTS: 13.6 +/- 4.7 GBq (188)Re-microspheres was administered selective in the feeding artery of the tumour to 10 patients (3 x HCC and 7 x colorectal liver metastases).
  • There was a low urinary excretion rate of 8.9 +/- 3.8% of administered activity within 96 h.
  • The absorbed dose to the tumour, normal liver (excluding the tumour) and bladder was 10.24 +/- 5.02 Gy/GBq (128 +/- 47 Gy), 3.94 +/- 2.52 Gy/GBq (50 +/- 33 Gy) and 0.27 +/- 0.20 Gy/GBq (2.4 +/- 1.9 Gy), respectively.
  • CONCLUSION: Treatment of colorectal liver metastases or HCC using high activities of (188)Re-microspheres was well tolerated and a PR was seen in 2 of 10 patients.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094017.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radioisotopes; 7440-15-5 / Rhenium
  •  go-up   go-down


66. Xu K, Zhu Z, Zeng F: Expression and significance of Oct4 in bladder cancer. J Huazhong Univ Sci Technolog Med Sci; 2007 Dec;27(6):675-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and significance of Oct4 in bladder cancer.
  • In order to detect the expression of Oct4 in bladder cancer tissue and cell line BIU-87, immunohistochemistry was used in 49 bladder cancer biopsy samples and immunofluorescence and reverse transcription-PCR were performed on bladder cancer cell line BIU-87.
  • Forty of 49 bladder cancer samples showed the expression of Oct4 in about 0.6% cancer cells.
  • The positive rate and density of Oct4 expression had no obvious relationship with the grade, recurrence or metastasis of bladder cancer (P>0.05).
  • A few Oct4 positive cells were found in bladder cancer cell line BIU-87, which was also confirmed by RT-PCR.
  • This study indicated the existence of few Oct4 positive cells in bladder cancer, which may be the bladder cancer stem cells.
  • This study may provide the foundation for isolation and identification of bladder cancer stem cells.
  • [MeSH-major] Neoplastic Stem Cells / pathology. Octamer Transcription Factor-3 / metabolism. Urinary Bladder Neoplasms / metabolism. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Cell Separation / methods. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18231740.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human
  •  go-up   go-down


67. Nakanishi Y, Arisawa C, Ando M: [Solitary metastasis to the urinary bladder from renal cell carcinoma: a case report]. Hinyokika Kiyo; 2006 Dec;52(12):937-9
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solitary metastasis to the urinary bladder from renal cell carcinoma: a case report].
  • A 48-year-old woman was referred to our hospital with a bladder mass which was detected by a general practitioner.
  • Ultrasonography showed a small bladder tumor and right renal mass.
  • Cystoscopy revealed a solitary, non papillary tumor at the right side of the retro-trigone.
  • Computed tomography revealed a large tumor at the right kidney.
  • Transurethral resection of the bladder tumor was performed.
  • The histopathological diagnosis was clear cell carcinoma.
  • There was no other distant metastasis.
  • Histopathologically, the right renal tumor showed clear cell carcinoma.
  • This was considered to be a case of a solitary metastatic bladder tumor from renal cell carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Urinary Bladder Neoplasms / secondary

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17252977.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 10
  •  go-up   go-down


68. Liu CX, Wen Y, Xu K, Zheng SB, Xu YW, Chen BS: [Expression of special AT-rich sequence-binding protein in bladder urothelial carcinoma and its clinical significance]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun;30(6):1389-91, 1394
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of special AT-rich sequence-binding protein in bladder urothelial carcinoma and its clinical significance].
  • OBJECTIVE: To detect the expression of special AT-rich sequence-binding protein (SATB1) in bladder urothelial carcinoma and investigate its correlation to the biological behavior of the carcinoma.
  • METHODS: The expression of SATB1 mRNA was detected in 34 cases of bladder urothelial carcinoma and 14 normal bladder tissues by RT-PCR, and the protein expression of SATB1 was detected in 68 cases of bladder urothelial carcinoma and 17 normal bladder tissues by immunohistochemistry.
  • The correlation between SATB1 expressions and the biological behavior of the tumor was analyzed.
  • RESULTS: The expression of SATB1 was significantly higher in bladder urothelial carcinoma tissues than in normal bladder tissues (P<0.05).
  • and the expression of SATB1 in the tumor tissues was correlated to the clinical stage and metastasis of the tumor.
  • CONCLUSION: SATB1 expression can be associated with the development and metastasis of bladder urothelial carcinoma and may potentially serve as an indicator for predicting the prognosis of bladder urothelial carcinoma.
  • [MeSH-major] Carcinoma / metabolism. Matrix Attachment Region Binding Proteins / metabolism. Urinary Bladder Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20584685.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Matrix Attachment Region Binding Proteins; 0 / RNA, Messenger; 0 / SATB1 protein, human
  •  go-up   go-down


69. Smith SC, Nicholson B, Nitz M, Frierson HF Jr, Smolkin M, Hampton G, El-Rifai W, Theodorescu D: Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination. Am J Pathol; 2009 Feb;174(2):371-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination.
  • Little is known about which genes mediate metastasis in bladder cancer, which accounts for much of the mortality of this disease.
  • We used human bladder cancer cell lines to develop models of two clinically common metastatic sites, lung and liver, and evaluated their gene expression with respect to human tumor tissues.
  • Parental cells were injected into either the murine spleen to generate liver metastases or tail vein to generate lung metastases with sequential progeny derived by re-injection and comparisons made of their organ-specific nature by crossed-site injections.
  • Both genomic and transcriptomic analyses of organ-selected cell lines found salient differences and shared core metastatic profiles, which were then screened against gene expression data from human tumors.
  • The expression levels of laminin V gamma 2 (LAMC2) contained in the core metastatic signature were increased as a function of human tumor stage, and its genomic location was in an area of gain as measured by comparative genomic hybridization.
  • Using immunohistochemistry in a human bladder cancer tissue microarray, LAMC2 expression levels were associated with tumor grade, but inversely with nodal status.
  • In contrast, in node-negative patients, LAMC2 expression was associated with visceral metastatic recurrence.
  • In summary, LAMC2 is a novel biomarker of bladder cancer metastasis that reflects the propensity of cells to metastasize via either lymphatic or hematogenous routes.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2000 Mar;27(3):252-63 [10679914.001]
  • [Cites] World J Gastroenterol. 2002 Oct;8(5):769-76 [12378613.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6418-23 [12438227.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6981-9 [12460916.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] Oncogene. 2004 Sep 2;23(40):6788-97 [15273733.001]
  • [Cites] Nat New Biol. 1973 Apr 4;242(118):148-9 [4512654.001]
  • [Cites] Cancer Metastasis Rev. 1989 Aug;8(2):98-101 [2673568.001]
  • [Cites] Clin Chem. 1996 Sep;42(9):1369-81 [8787692.001]
  • [Cites] Cancer Res. 1952 Oct;12(10):734-8 [12988203.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7813-21 [15520187.001]
  • [Cites] J Biol Chem. 2005 Jan 7;280(1):88-93 [15525652.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):44-55 [15630443.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Genes Chromosomes Cancer. 2005 May;43(1):25-36 [15723340.001]
  • [Cites] Hum Pathol. 2005 May;36(5):522-30 [15948119.001]
  • [Cites] Nature. 2005 Jul 28;436(7050):518-24 [16049480.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):93-5 [16098461.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7320-7 [16103083.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):713-25 [16110317.001]
  • [Cites] Clin Exp Metastasis. 2005;22(7):533-8 [16475023.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1917-22 [16488989.001]
  • [Cites] Neoplasia. 2006 Mar;8(3):181-9 [16611411.001]
  • [Cites] Curr Opin Urol. 2006 Sep;16(5):367-71 [16905984.001]
  • [Cites] Cell. 2006 Nov 17;127(4):679-95 [17110329.001]
  • [Cites] Br J Cancer. 2007 Feb 12;96(3):417-23 [17211480.001]
  • [Cites] J Natl Cancer Inst. 2007 Feb 21;99(4):309-21 [17312308.001]
  • [Cites] J Surg Res. 2007 Apr;138(2):284-90 [17254608.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63 [17548814.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3803-13 [17606711.001]
  • [Cites] J Clin Pathol. 2008 Mar;61(3):307-10 [17586680.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Apr;5(4):206-19 [18253104.001]
  • [Cites] J Gastrointest Surg. 2008 May;12(5):966-80 [18181006.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):283-4 [18835030.001]
  • (PMID = 19147813.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / T32 GM007267; United States / NCI NIH HHS / CA / R01 CA075115; United States / NCI NIH HHS / CA / CA009109; United States / NCI NIH HHS / CA / R01 CA075115-12; United States / NIGMS NIH HHS / GM / T32GM007267; United States / NCI NIH HHS / CA / CA075115-12; United States / NCI NIH HHS / CA / R29 CA075115; United States / NCI NIH HHS / CA / CA075115; United States / NCI NIH HHS / CA / T32 CA009109
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / LAMC2 protein, human; 0 / Laminin
  • [Other-IDs] NLM/ PMC2630547
  •  go-up   go-down


70. Lekas A, Papathomas TG, Papatsoris AG, Deliveliotis C, Lazaris AC: Novel therapeutics in metastatic bladder cancer. Expert Opin Investig Drugs; 2008 Dec;17(12):1889-99
Hazardous Substances Data Bank. PLATINUM COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel therapeutics in metastatic bladder cancer.
  • BACKGROUND: Albeit transitional cell carcinoma of the urinary bladder is a chemosensitive neoplasm, metastatic disease is related with poor prognosis and short-term survival data.
  • OBJECTIVE: Cisplatin-based combination chemotherapy is recognised as the golden standard therapy for patients with inoperable locally advanced or metastatic bladder cancer.
  • METHODS: Reviewing the current status and addressing the future of novel anticancer therapeutics in metastatic urinary bladder cancer.
  • [MeSH-major] Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Humans. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / genetics. Neoplasm Metastasis / pathology. Platinum Compounds / therapeutic use

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19012504.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platinum Compounds
  • [Number-of-references] 120
  •  go-up   go-down


71. Black PC, Dinney CP: Bladder cancer angiogenesis and metastasis--translation from murine model to clinical trial. Cancer Metastasis Rev; 2007 Dec;26(3-4):623-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder cancer angiogenesis and metastasis--translation from murine model to clinical trial.
  • In the majority of cases, death from bladder cancer results from metastatic disease.
  • Understanding the closely linked mechanisms of invasion, metastasis and angiogenesis in bladder cancer has allowed us to develop new therapeutic strategies that harbor the promise of decisive improvements in patient survival.
  • The essential link between cell based experiments and the translation of novel agents into human patients with bladder cancer is the animal model.
  • With emphasis on the orthotopic xenograft model, this review outlines some key mechanisms relevant to angiogenesis and the development of metastasis in bladder cancer.
  • Although imperfect in their translatability into clinical efficacy, animal models remain a critical tool in bladder cancer research.
  • [MeSH-major] Carcinoma, Transitional Cell / blood supply. Neoplasm Metastasis. Neovascularization, Pathologic / etiology. Urinary Bladder Neoplasms / blood supply
  • [MeSH-minor] Animals. Clinical Trials as Topic. Disease Models, Animal. Humans. Interleukin-8 / genetics. Matrix Metalloproteinase 9 / genetics. Mice. Neoplasm Invasiveness. Neoplasm Transplantation. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Vascular Endothelial Growth Factor A / genetics

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17726580.001).
  • [ISSN] 0167-7659
  • [Journal-full-title] Cancer metastasis reviews
  • [ISO-abbreviation] Cancer Metastasis Rev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA91846
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Interleukin-8; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Number-of-references] 116
  •  go-up   go-down


72. Retz M, Sidhu SS, Lehmann J, Tamamura H, Fujii N, Basbaum C: New HIV-drug inhibits in vitro bladder cancer migration and invasion. Eur Urol; 2005 Dec;48(6):1025-30
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New HIV-drug inhibits in vitro bladder cancer migration and invasion.
  • OBJECTIVE: The CXCR4/CXCL12 axis appears crucial in the metastasis of bladder cancer.
  • Our aim was to evaluate the potency of the CXCR4 antagonist, 4F-benzoyl-TE14011 (4F-bTE), as an anti-metastatic drug in this disease.
  • In this study, we assessed the ability of 4F-bTE to inhibit tumor cell motility, invasion through extracellular matrix (ECM), matrix metalloproteinase (MMP) secretion and cytoskeletal responses to chemokine.
  • METHODS: To assess the degree to which cells could migrate and invade ECM under various conditions, we used TCCSUP bladder cancer cells in a Boyden chamber system.
  • To assess the effects of the CXCR4 antagonist 4F-bTE on each of the above parameters, we exposed bladder cancer cells either to chemokine CXCL12, alone, or to both CXCL12 and 4F-bTE.
  • RESULTS: The CXCR4 antagonist 4F-bTE markedly decreased CXCL12-induced bladder cancer cell migration and ECM invasion in Boyden chamber assays.
  • CONCLUSION: The CXCR4 antagonist 4F-bTE has the potential to inhibit expression of the metastatic phenotype and may provide therapeutic value to patients.
  • [MeSH-major] Anti-HIV Agents / pharmacology. Neoplasm Invasiveness / pathology. Receptors, Interleukin-8B / antagonists & inhibitors. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Cell Movement / drug effects. Cell Proliferation / drug effects. Chemokines, CXC / physiology. Chemotaxis / drug effects. Humans. In Vitro Techniques. Probability. Sensitivity and Specificity. Statistics, Nonparametric. Tumor Cells, Cultured / cytology

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140456.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Chemokines, CXC; 0 / Receptors, Interleukin-8B
  •  go-up   go-down


73. Zu X, Tang Z, Li Y, Gao N, Ding J, Qi L: Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. BJU Int; 2006 Nov;98(5):1090-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis.
  • OBJECTIVE: To elucidate the role of vascular endothelial growth factor-C (VEGF-C) in bladder transitional cell carcinoma (TCC), examining VEGF-C expression in bladder TCC tissue and the association of VEGF-C with clinicopathological features, as the expression of VEGF-C in several carcinomas is significantly associated with angiogenesis, lymphangiogenesis and regional lymph node metastasis, but there are few reports of VEGF-C expression in bladder TCC.
  • PATIENTS AND METHODS: The study included 45 patients with bladder TCC; VEGF-C expression was assessed by immunohistochemistry and the association between VEGF-C expression and angiogenesis, as evaluated by microvessel density (MVD), was examined.
  • RESULTS: There was VEGF-C expression in the cytoplasm of tumour cells, but very little in the normal transitional epithelium.
  • VEGF-C expression was significantly associated with tumour size, pathological T stage, pathological grade, lymphatic-venous involvement and pelvic lymph node metastasis (all P < 0.05).
  • Multivariate analysis showed that VEGF-C expression was an exclusive independent factor influencing pelvic lymph node metastasis.
  • A multivariate analysis based on the Cox proportional hazard model showed that lymph node metastasis was only an independent prognostic factor in the multivariate analysis using the Cox regression model (P = 0.010).
  • CONCLUSION: The present study provides evidence supporting the involvement of VEGF-C expression in the promotion of lymph node metastasis in bladder TCC.
  • Examination of VEGF-C expression in biopsy specimens might be beneficial in predicting pelvic lymph node metastasis.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Urinary Bladder Neoplasms / pathology. Vascular Endothelial Growth Factor C / metabolism
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Neovascularization, Pathologic. Prognosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17034609.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


74. Seya T, Tanaka N, Shinji S, Yokoi K, Oguro T, Oaki Y, Ishiwata T, Naito Z, Tajiri T: Squamous cell carcinoma arising from recurrent anal fistula. J Nippon Med Sch; 2007 Aug;74(4):319-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor was observed to be continuous from the external opening but was not exposed to the internal opening of the rectal mucosa.
  • Histopathological examination revealed no remnant cancer tissue or lymph node metastasis.
  • Urological examination revealed urinary bladder cancer, and transurethral resection of the bladder tumor was performed.
  • Histopathological examination revealed transitional cell carcinoma of the urinary bladder.
  • Two years later, the patient died of metastatic urinary bladder cancer, without recurrence of the fistula cancer.
  • Because the patients mother had died of urinary bladder cancer and she herself had metachronous urinary bladder cancer in addition to fistula cancer, we investigated whether microsatellite instability (MSI) and chromosomal instability correlated with fistula cancer development.
  • Immunohistochemical analysis of formalin-fixed, paraffin-embedded surgical tumor specimens for p53, MLH1, and MSH2 was performed.
  • The tumor specimens showed no MLH1 expression but did show normal MSH2 expression. p53 was not expressed.
  • Five microsatellite loci were examined using the tumor specimens to detect MSI, namely two loci with mononucleotide runs (i.e., BAT25 and BAT26) and three loci with dinucleotide repeats (i.e., APC, Mfd15, and D2S123).
  • The tumor specimens showed alternations in the repeated sequences of two loci (i.e., BAT26 and D2S123).
  • As a result, the tumor was classified as MSI-H (high) according to the Bethesda criteria.
  • [MeSH-minor] Carcinoma, Transitional Cell / pathology. Female. Humans. Microsatellite Instability. Middle Aged. Neoplasms, Second Primary / pathology. Recurrence. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17878704.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


75. Eisenhardt A, Frey U, Tack M, Rosskopf D, Lümmen G, Rübben H, Siffert W: Expression analysis and potential functional role of the CXCR4 chemokine receptor in bladder cancer. Eur Urol; 2005 Jan;47(1):111-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analysis and potential functional role of the CXCR4 chemokine receptor in bladder cancer.
  • OBJECTIVE: Recent analysis gave evidence for the fact that the chemokine receptor CXCR4 is of functional significance in the multistep procedure of metastasis directing tumor cells to their metastatic target organs.
  • In our study we investigated the expression of the CXCR4 receptor on bladder cancer cells and the functional activation of the CXCR4 receptor in bladder cancer cell lines regarding signal transduction pathways, which are involved in metastasis.
  • METHODS: Receptor transcript expression was analysed and quantified by reverse transcription PCR with RNA extracted from different samples of native human bladder cancer tissue, normal urothelium and the bladder cancer cell lines J82 and T24.
  • Measurement of intracellular [Ca(++)](i) and analysis of intracellular stress fiber formation, chemotaxis, Matrigel invasion and proliferation were performed in the bladder cancer cell lines J82 and T24 upon stimulation with the specific agonist SDF-1.
  • RESULTS: Specific CXCR4 receptor transcripts were detected in normal urothelium, the bladder cancer cell lines J82 and T24 and in all bladder carcinoma specimens.
  • We did not observe a quantitative correlation of transcript expression and tumor stage.
  • While SDF-1 did not evoke increases in [Ca(++)](i) in bladder cancer cell lines, we observed a distinct rise in intracellular stress fiber formation, chemotactic activity, invasion through Matrigel coated membranes and cell growth upon stimulation with SDF-1, which was blocked in the presence of a specific CXCR4 receptor antibody.
  • CONCLUSION: Our results support that the chemokine receptor CXCR4 is an interesting candidate for the future investigation of metastasis of bladder cancer in vivo.
  • [MeSH-major] Receptors, CXCR4 / biosynthesis. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Chemokine CXCL12. Chemokines, CXC / pharmacology. Humans. RNA, Messenger / biosynthesis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15582259.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / RNA, Messenger; 0 / Receptors, CXCR4
  •  go-up   go-down


76. Su Y, Qiu Q, Zhang X, Jiang Z, Leng Q, Liu Z, Stass SA, Jiang F: Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomarkers Prev; 2010 Feb;19(2):327-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer.
  • Aldehyde dehydrogenase 1 A1 (ALDH1A1) has recently been suggested as a marker for cancer stem or stem-like cancer cells of some human malignancies.
  • The purpose of this study was to investigate the stem cell-related function and clinical significance of the ALDH1A1 in bladder urothelial cell carcinoma.
  • Aldefluor assay was used to isolate ALDH1A1+ cells from bladder cancer cells.
  • Immunohistochemistry was done for evaluating ALDH1A1 expression on 22 normal bladder tissues and 216 bladder tumor specimens of different stage and grade.
  • The ALDH1A1+ cancer cells displayed higher in vitro tumorigenicity compared with isogenic ALDH1A1- cells.
  • The ALDH1A1+ cancer cells could generate xenograft tumors that resembled the histopathologic characteristics and heterogeneity of the parental cells.
  • High ALDH1A1 expression was found in 26% (56 of 216) of human bladder tumor specimens and significantly related to advanced pathologic stage, high histologic grade, recurrence and progression, and metastasis of bladder urothelial cell carcinomas (all P < 0.05).
  • Furthermore, ALDH1A1 expression was inversely associated with cancer-specific and overall survivals of the patients (P = 0.027 and 0.030, respectively).
  • Therefore, ALDH1A1+ cell population could be enriched in tumor-initiating cells.
  • ALDH1A1 may serve as a useful marker for monitoring the progression of bladder tumor and identifying bladder cancer patients with poor prognosis who might benefit from adjuvant and effective treatments.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3382-9 [19336570.001]
  • [Cites] Mol Cancer Res. 2009 Mar;7(3):330-8 [19276181.001]
  • [Cites] Stem Cells. 2009 Jul;27(7):1487-95 [19544456.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14016-21 [19666525.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):39747-53 [10995752.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] J Urol. 2002 Mar;167(3):1282-7 [11832714.001]
  • [Cites] Life Sci. 1980 May 26;26(21):1773-80 [6985464.001]
  • [Cites] Genomics. 1989 Nov;5(4):857-65 [2591967.001]
  • [Cites] J Biol Chem. 1995 Jul 21;270(29):17521-7 [7615557.001]
  • [Cites] Stem Cells. 2004;22(7):1142-51 [15579635.001]
  • [Cites] Stem Cells. 2005 Jun-Jul;23(6):752-60 [15917471.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):678-86 [16129368.001]
  • [Cites] Stem Cells Dev. 2005 Aug;14(4):367-77 [16137225.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):713-25 [16110317.001]
  • [Cites] Urology. 2005 Dec;66(6 Suppl 1):64-74 [16399416.001]
  • [Cites] Blood. 2006 Mar 1;107(5):2162-9 [16269619.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11707-12 [16857736.001]
  • [Cites] N Engl J Med. 2006 Sep 21;355(12):1253-61 [16990388.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9339-44 [16990346.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6796-805 [17638891.001]
  • [Cites] Lung Cancer. 2008 Mar;59(3):340-9 [17920722.001]
  • [Cites] Stem Cells. 2008 Mar;26(3):611-20 [18055447.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1701-6 [18347170.001]
  • [Cites] Nat Genet. 2008 May;40(5):499-507 [18443585.001]
  • [Cites] Cancer Invest. 2008 Aug;26(7):725-33 [18608209.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6281-91 [18676852.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):485-7 [18938743.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):555-67 [18371393.001]
  • [Cites] Cancer Biol Ther. 2008 Oct;7(10):1663-8 [18787416.001]
  • [Cites] Mol Cancer. 2008;7:87 [19025616.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Jul 31;385(3):307-13 [19450560.001]
  • (PMID = 20142235.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA135382; United States / NCI NIH HHS / CA / CA-137742; United States / NCI NIH HHS / CA / CA-133956; United States / NCI NIH HHS / CA / R03 CA137742; United States / NCI NIH HHS / CA / R01 CA161837; United States / NCI NIH HHS / CA / CA-135382; United States / NCI NIH HHS / CA / R03 CA133956
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.2.1.3 / ALDH1A1 protein, human; EC 1.2.1.3 / Aldehyde Dehydrogenase
  • [Other-IDs] NLM/ NIHMS162658; NLM/ PMC3544173
  •  go-up   go-down


77. Tasci AI, Tugcu V, Ozbek E, Ozbay B, Simsek A, Koksal V: A single-nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances bladder cancer susceptibility. BJU Int; 2008 Feb;101(4):503-7
MedlinePlus Health Information. consumer health - Smoking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances bladder cancer susceptibility.
  • OBJECTIVE: To explore the association between the promoter polymorphism (that influences the transcriptional level) of matrix metalloproteinase-1 (MMP-1, associated with tumour cell invasion and metastasis) and bladder cancer in a Turkish population.
  • PATIENTS, SUBJECTS AND METHODS: The MMP-1 polymorphism was assessed in 102 transitional cell carcinomas of the bladder (50 Ta, 52 T2-4) and in 94 age-, smoking- and gender-matched healthy volunteers.
  • Of the 102 cases with bladder cancer, 49 (48%) showed the 2G/2G genotype, whereas it was found in 22 of the 94 controls (23%); this difference was statistically significant (P < 0.01; odds ratio 2.79, 95% confidence interval, CI, 1.53-5.60).
  • However, there was no significant association between the 2G/2G genotype and tumour grade and pathological stage.
  • CONCLUSION: These results suggest that the MMP-1 promoter polymorphism might be linked to susceptibility for bladder cancer.
  • [MeSH-major] Carcinoma, Transitional Cell / genetics. Genetic Predisposition to Disease / genetics. Matrix Metalloproteinase 1 / genetics. Promoter Regions, Genetic / genetics. Smoking / adverse effects. Urinary Bladder Neoplasms / genetics

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986285.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


78. Ohyama C: Glycosylation in bladder cancer. Int J Clin Oncol; 2008 Aug;13(4):308-13
Hazardous Substances Data Bank. HYALURONIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glycosylation in bladder cancer.
  • There is a distinct difference in carbohydrate profiles between normal and tumor tissues.
  • The characteristic carbohydrate expression associated with malignant transformation is caused by "aberrant glycosylation" catalyzed by specific glycosyltransferases and glycosidases.
  • A close relationship between blood type antigens and bladder cancer was first established in the 1960s, using the classic red-cell adherence test.
  • In the 1980s, several monoclonal antibodies were raised against complex carbohydrates, and the clinico-pathologic significance of blood type antigens in bladder cancer was investigated using these antibodies.
  • Other than blood type antigens, the significance of aberrant glycosylation in bladder cancer has been demonstrated in a number of articles.
  • For instance, overexpression of the ganglioside (an acidic glycosphingolipid which has sialic acid) GM3 induces apoptosis and reduces invasive potential in a bladder cancer cell line.
  • Hyaluronic acid promotes tumor metastasis and is an accurate diagnostic marker for bladder cancer.
  • The expression of N-acetylglucosaminyltransferase V and beta,1-6 branching N-linked oligosaccharides is closely related to low malignant potential in bladder cancer.
  • Selectins and galectins, specific ligands for carbohydrate antigens, are also key molecules involved in the apoptosis and metastasis of cancer cells.
  • Thus, proteoglycans, glycoproteins, and glycosphingolipids, and their ligands, play crucial roles in the malignant transformation, invasion, and metastasis of bladder cancer.
  • [MeSH-major] Carbohydrate Metabolism. Urinary Bladder Neoplasms / metabolism

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18704630.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Blood Group Antigens; 0 / Galectins; 0 / Gangliosides; 0 / Glycosphingolipids; 0 / Membrane Glycoproteins; 0 / Proteoglycans; 9004-61-9 / Hyaluronic Acid; EC 3.2.1.35 / Hyaluronoglucosaminidase
  • [Number-of-references] 42
  •  go-up   go-down


79. Mitra AP, Almal AA, George B, Fry DW, Lenehan PF, Pagliarulo V, Cote RJ, Datar RH, Worzel WP: The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. BMC Cancer; 2006 Jun 16;6:159
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer.
  • BACKGROUND: Previous studies on bladder cancer have shown nodal involvement to be an independent indicator of prognosis and survival.
  • This study aimed at developing an objective method for detection of nodal metastasis from molecular profiles of primary urothelial carcinoma tissues.
  • METHODS: The study included primary bladder tumor tissues from 60 patients across different stages and 5 control tissues of normal urothelium.
  • These were then used in a voting algorithm to classify the validation set samples into those associated with or without nodal metastasis.
  • Rules generated using only ICAM1, MAP2K6 and KDR were comparably robust, with a single representative rule producing an accuracy of 90% when used by itself on the validation set, suggesting a crucial role for these genes in nodal metastasis.
  • CONCLUSION: Our study demonstrates the use of standardized quantitative gene expression values from primary bladder tumor tissues as inputs in a genetic programming system to generate classifier rules for determining the nodal status.
  • Further studies are needed to identify more class-specific signatures and confirm the role of these genes in the evolution of nodal metastasis in bladder cancer.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2000 May;85(7):817-23 [10792159.001]
  • [Cites] Radiology. 1982 Apr;143(1):29-36 [7063747.001]
  • [Cites] Eur J Biochem. 2000 Aug;267(15):4720-30 [10903505.001]
  • [Cites] Free Radic Biol Med. 2000 May 1;28(9):1379-86 [10924857.001]
  • [Cites] Nature. 2000 Sep 7;407(6800):102-6 [10993082.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):666-75 [11157016.001]
  • [Cites] J Immunol. 2001 Jun 1;166(11):6877-84 [11359848.001]
  • [Cites] Am J Hum Genet. 2001 Jul;69(1):138-47 [11404819.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(14):4604-13 [11416138.001]
  • [Cites] Mutat Res. 2001 Sep 1;480-481:349-58 [11506827.001]
  • [Cites] Mol Diagn. 2001 Dec;6(4):217-25 [11774186.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Apr 26;293(1):509-16 [12054630.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8054-9 [12060752.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2766-74 [12231515.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6966-72 [12460914.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):90-6 [12469123.001]
  • [Cites] Urol Int. 2003;70(3):167-71 [12660451.001]
  • [Cites] Thromb Haemost. 2003 Jun;89(6):1089-97 [12783123.001]
  • [Cites] Histopathology. 2003 Sep;43(3):272-9 [12940780.001]
  • [Cites] Cancer Sci. 2003 Sep;94(9):751-6 [12967471.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5454-61 [14500381.001]
  • [Cites] Curr Mol Med. 2003 Nov;3(7):631-42 [14601637.001]
  • [Cites] Nature. 1999 Apr 29;398(6730):824-8 [10235266.001]
  • [Cites] Urology. 1999 Sep;54(3):567-72 [10475375.001]
  • [Cites] Radiology. 2004 Nov;233(2):449-56 [15375228.001]
  • [Cites] Exp Cell Res. 2005 Feb 15;303(2):321-30 [15652346.001]
  • [Cites] Circulation. 2005 Jan 25;111(3):349-55 [15642762.001]
  • [Cites] Cell Res. 2005 Jan;15(1):11-8 [15686620.001]
  • [Cites] J Biol Chem. 2005 Apr 15;280(15):14675-83 [15677464.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):943-50 [15774488.001]
  • [Cites] Rays. 2004 Oct-Dec;29(4):373-6 [15852722.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3773-7 [15897575.001]
  • [Cites] BJU Int. 2005 Jul;96(1):7-12 [15963111.001]
  • [Cites] Genomics. 1994 Apr;20(3):463-7 [8034319.001]
  • [Cites] Nature. 1995 Mar 9;374(6518):193-6 [7877695.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8871-5 [7568034.001]
  • [Cites] Stat Med. 1997 Oct 15;16(19):2143-56 [9330425.001]
  • [Cites] Am J Respir Cell Mol Biol. 1998 Jul;19(1):6-17 [9651175.001]
  • [Cites] Mol Cell. 1998 Aug;2(2):213-22 [9734358.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6533-9 [16116151.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2005 Dec;27(12):1988-95 [16355665.001]
  • [Cites] Nat Clin Pract Urol. 2004 Nov;1(1):4-5 [16474441.001]
  • [Cites] BMC Bioinformatics. 2006;7:16 [16409628.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):499-506 [14745865.001]
  • [Cites] Microbiol Mol Biol Rev. 2004 Jun;68(2):320-44 [15187187.001]
  • [Cites] Mol Cancer. 2004 Jan 23;3:5 [14741054.001]
  • [Cites] Traffic. 2004 Aug;5(8):571-6 [15260827.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1166-70 [15336964.001]
  • [Cites] Mol Cell. 2000 Apr;5(4):753-60 [10882111.001]
  • (PMID = 16780590.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA065726; United States / NCI NIH HHS / CA / CA-86871; United States / NCI NIH HHS / CA / CA-65726; United States / NCI NIH HHS / CA / P01 CA086871; United States / NCI NIH HHS / CA / CA-70903
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Validation Studies
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1550424
  •  go-up   go-down


80. Suzuki K, Morita T, Tokue A: Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. Int J Urol; 2005 Feb;12(2):152-8
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder.
  • PURPOSE: It has been found that expression of vascular endothelial growth factor-C (VEGF-C) in several carcinomas is significantly associated with angiogenesis, lymphangiogenesis and regional lymph node metastasis.
  • However, VEGF-C expression in bladder transitional cell carcinoma (TCC) has not yet been reported.
  • To elucidate the role of VEGF-C in bladder TCC, we examined VEGF-C expression in bladder TCC and pelvic lymph node metastasis specimens obtained from patients who underwent radical cystectomy.
  • METHODS: Eighty-seven patients who underwent radical cystectomy for clinically organ-confined TCC of the bladder were enrolled in the present study.
  • No neoadjuvant treatments, except transurethral resection of the tumor, were given to these patients.
  • The VEGF-C expressions of 87 bladder tumors and 20 pelvic lymph node metastasis specimens were examined immunohistochemically and the association between VEGF-C expression and clinicopathological factors, including angiogenesis as evaluated by microvessel density (MVD), was also examined.
  • RESULTS: Vascular endothelial growth factor-C expression was found in the cytoplasm of tumor cells, but not in the normal transitional epithelium.
  • Vascular endothelial growth factor-C expression was significantly associated with the pathological T stage (P = 0.0289), pelvic lymph node metastasis (P < 0.0001), lymphatic involvement (P = 0.0008), venous involvement (P = 0.0002) and high MVD (P = 0.0043).
  • The multivariate analysis demonstrated that VEGF-C expression and high MVD in bladder TCC were independent risk factors influencing the pelvic lymph node metastasis.
  • The multivariate analysis based on Cox proportional hazard model showed that the independent prognostic factors were patient age (P = 0.0132) and pelvic lymph node metastasis (P = 0.0333).
  • CONCLUSION: The present study suggests that VEGF-C expression is an important predictive factor of pelvic lymph node metastasis in bladder cancer patients.
  • [MeSH-major] Carcinoma, Transitional Cell / metabolism. Urinary Bladder Neoplasms / metabolism. Vascular Endothelial Growth Factor C / metabolism
  • [MeSH-minor] Age Factors. Aged. Antigens, CD34 / metabolism. Cystectomy. Cytoplasm / metabolism. Epithelium / metabolism. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Multivariate Analysis. Neovascularization, Pathologic. Pelvis. Prognosis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15733109.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


81. Wu CL, Shieh GS, Chang CC, Yo YT, Su CH, Chang MY, Huang YH, Wu P, Shiau AL: Tumor-selective replication of an oncolytic adenovirus carrying oct-3/4 response elements in murine metastatic bladder cancer models. Clin Cancer Res; 2008 Feb 15;14(4):1228-38
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-selective replication of an oncolytic adenovirus carrying oct-3/4 response elements in murine metastatic bladder cancer models.
  • PURPOSE: Oncolytic adenoviruses are attractive therapeutics for cancer because they selectively replicate in tumors.
  • However, targeting tumor metastasis remains a major challenge for current virotherapy for cancer.
  • Oct-3/4 is specifically expressed in embryonic stem cells and tumor cells.
  • Oct-3/4 highly expressed in cancer cells may be a potential target for cancer therapy.
  • We developed an E1B-55 kDa-deleted adenovirus, designated Ad.9OC, driven by nine copies of Oct-3/4 response element for treating Oct-3/4-expressing metastatic bladder cancer.
  • EXPERIMENTAL DESIGN: We examined the expression of Oct-3/4 in human bladder tumor tissues and bladder cancer cell lines.
  • We also evaluated the cytolytic and antitumor effects of Ad.9OC on bladder cancer cells in vitro and in vivo.
  • RESULTS: Oct-3/4 expression was detected in bladder cancer cell lines, as well as in human bladder tumor tissues.
  • Notably, Oct-3/4 expression was higher in metastatic compared with nonmetastatic bladder cancer cells.
  • Ad.9OC induced higher cytolytic activity in metastatic bladder cancer cells than in their nonmetastatic counterparts, whereas it did not cause cytotoxicity in normal cells.
  • Pharmacologic and short hairpin RNA-mediated Oct-3/4 inhibition rendered bladder cancer cells more resistant to Ad.9OC-induced cytolysis.
  • Replication of Ad.9OC was detected in murine bladder cancer cells and bladder tumor tissues.
  • We also showed the effectiveness of Ad.9OC for treating bladder cancer in subcutaneous, as well as metastatic, bladder tumor models.
  • Especially, metastatic bladder tumors are good target for Ad.9OC treatment.
  • [MeSH-major] Octamer Transcription Factor-3 / metabolism. Oncolytic Virotherapy / methods. Oncolytic Viruses / genetics. Urinary Bladder Neoplasms / therapy. Urinary Bladder Neoplasms / virology
  • [MeSH-minor] Adenoviridae / genetics. Animals. Cell Line, Tumor. Disease Models, Animal. Humans. Immunoblotting. Immunohistochemistry. Mice. Response Elements / genetics. Reverse Transcriptase Polymerase Chain Reaction. Transcriptional Activation. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281558.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Octamer Transcription Factor-3
  •  go-up   go-down


82. Abdel Wahab AH, Abo-Zeid HI, El-Husseini MI, Ismail M, El-Khor AM: Role of loss of heterozygosity on chromosomes 8 and 9 in the development and progression of cancer bladder. J Egypt Natl Canc Inst; 2005 Dec;17(4):260-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of loss of heterozygosity on chromosomes 8 and 9 in the development and progression of cancer bladder.
  • BACKGROUND: Loss of heterozygosity (LOH) in tumor samples is believed to be a marker for the absence of a functional tumor suppressor gene.
  • Non-random chromosome deletion and LOH at specific chromosomal regions are identified in a number of common human cancers including carcinoma of the bladder, which is considered the most predominant cancer in Egypt due to the prevalence of schistosomiasis.
  • PURPOSE: The main objective of the present study is to clarify the role of chromosomes 8 and 9 in the establishment and/or progression of schistosomiasis-related bladder cancer through detection of LOH of 8 microsatellite markers on both chromosomes.
  • It also aims to compare the LOH pattern of the tested markers between schistosomiasis- associated and non schistosomiasis-associated bladder cancer.
  • MATERIAL AND METHODS: To achieve this purpose, DNA was extracted from the tumor specimens and the corresponding peripheral blood samples of 42 primary bladder cancer patients (schistosomal and non schistosomal).
  • Deletions at chromosome 8 were shown to be associated with high grade of the tumor and LOH at D8S85 was associated with metastatic lymph nodes.
  • CONCLUSION: Our data indicate that more than one tumor suppressor gene on chromosomes 8 and 9 are involved in high grades of bladder carcinogenesis, one at 8p12 and another at 8q21.1 regions.
  • Also, a region at 8q23-quarter may harbor tumor suppressor gene that involved in metastasis of bladder cancer.
  • Our study also revealed that 9p21 (p16INK4) region is involved in both types of the tumor (SCC & TCC).
  • Region 9q12-13 is considered to be a critical region of urothelial tumor suppressor genes.
  • Finally, the present study shows no line of demarcation between schistosomiasis-associate and non schistosomiasis-associated bladder cancer in terms of LOH of the tested microsatellite markers on chromosome 8 and 9.
  • This suggests that data obtained from schistosoma-associated bladder cancer can be extrapolated to bladder cancer induced by a schistosomiasis independent mechanism.
  • [MeSH-major] Chromosomes, Human, Pair 8 / genetics. Chromosomes, Human, Pair 9 / genetics. Loss of Heterozygosity. Schistosomiasis haematobia / complications. Urinary Bladder Neoplasms / genetics
  • [MeSH-minor] DNA, Neoplasm / analysis. Disease Progression. Humans. Microsatellite Repeats. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17102820.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


83. Djaladat H, Mehrsai A, Nasseh H, Pourmand G: Synchronous renal fossa recurrence with bladder metastases due to renal cell carcinoma. Urol J; 2005;2(3):169-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous renal fossa recurrence with bladder metastases due to renal cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17602423.001).
  • [ISSN] 1735-1308
  • [Journal-full-title] Urology journal
  • [ISO-abbreviation] Urol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


84. Cui R, Li F, Zhuang H: Interesting image. Two primary colon cancers shown on FDG PET/CT performed to evaluate possible lung metastases from bladder cancer. Clin Nucl Med; 2010 Jan;35(1):53-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interesting image. Two primary colon cancers shown on FDG PET/CT performed to evaluate possible lung metastases from bladder cancer.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Fluorodeoxyglucose F18. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Neoplasms, Multiple Primary / diagnosis. Positron-Emission Tomography. Tomography, X-Ray Computed. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026981.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


85. Serrano Frago P, Gil Martínez P, Medrano Llorente P, Allué López M, Rioja Sanz LA: [Unusual iconography of metastasis of bladder infiltrating transitional carcinoma]. Arch Esp Urol; 2006 Jun;59(5):546
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unusual iconography of metastasis of bladder infiltrating transitional carcinoma].
  • [Transliterated title] Iconografía inusual de metastasis de carcinoma transicional infiltrante de vejiga.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Lymphatic Metastasis. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16903563.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


86. Sgambato A, Buffon RB, Cota C, Matroianni A, Ardigò M: In vivo reflectance confocal microscopy for cutaneous metastasis of bladder adenocarcinoma. Arch Dermatol; 2009 Feb;145(2):213-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo reflectance confocal microscopy for cutaneous metastasis of bladder adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Microscopy, Confocal. Scalp. Skin Neoplasms / secondary. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19221283.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


87. Schuurman JP, de Vries Reilingh TS, Roothaan SM, Bijleveld RT, Wiezer MJ: Urinary bladder metastasis from an esophageal adenocarcinoma: a case report. Am J Gastroenterol; 2009 Jun;104(6):1603-4
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary bladder metastasis from an esophageal adenocarcinoma: a case report.
  • [MeSH-major] Adenocarcinoma / secondary. Esophageal Neoplasms / pathology. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Diagnosis, Differential. Endoscopy, Gastrointestinal. Follow-Up Studies. Humans. Immunohistochemistry. Keratin-7 / analysis. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19491880.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-7
  •  go-up   go-down


88. Lin WC, Chen JH: Urinary bladder metastasis from breast cancer with heterogeneic expression of estrogen and progesterone receptors. J Clin Oncol; 2007 Sep 20;25(27):4308-10
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary bladder metastasis from breast cancer with heterogeneic expression of estrogen and progesterone receptors.
  • [MeSH-major] Breast Neoplasms / pathology. Gene Expression Regulation, Neoplastic. Receptors, Estrogen / biosynthesis. Receptors, Progesterone / biosynthesis. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Aged. Female. Humans. Neoplasm Metastasis. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17878482.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


89. Basu S, Houseni M, Alavi A: (18)F-FDG-PET in restaging primary maxillary sinus melanoma with isolated gall bladder metastasis. Hell J Nucl Med; 2009 May-Aug;12(2):170
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (18)F-FDG-PET in restaging primary maxillary sinus melanoma with isolated gall bladder metastasis.
  • [MeSH-major] Fluorodeoxyglucose F18. Gallbladder Neoplasms / radionuclide imaging. Gallbladder Neoplasms / secondary. Maxillary Sinus Neoplasms / radionuclide imaging. Melanoma / radionuclide imaging. Melanoma / secondary. Positron-Emission Tomography / methods
  • [MeSH-minor] Aged. Female. Humans. Neoplasm Staging. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19675875.001).
  • [ISSN] 1790-5427
  • [Journal-full-title] Hellenic journal of nuclear medicine
  • [ISO-abbreviation] Hell J Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


90. Morikawa T, Nishimatsu H, Kadono T, Homma Y, Fukayama M: Urinary bladder metastasis from extramammary Paget's disease in a patient with a past history of colon and gastric cancers. Pathol Int; 2010 Feb;60(2):145-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary bladder metastasis from extramammary Paget's disease in a patient with a past history of colon and gastric cancers.
  • [MeSH-major] Neoplasms, Second Primary / pathology. Paget Disease, Extramammary / secondary. Soft Tissue Neoplasms / secondary. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20398202.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Australia
  •  go-up   go-down


91. McAchran SE, Williams DH, MacLennan GT: Renal cell carcinoma metastasis to the bladder. J Urol; 2010 Aug;184(2):726-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma metastasis to the bladder.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Urinary Bladder Neoplasms / secondary






Advertisement